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ABSTRACT 
Difficult-to-express (DTE) recombinant proteins like multi-specific proteins, DTE monoclonal 
antibodies and lysosomal enzymes, have seen difficulties in manufacturability using Chinese 
hamster ovary (CHO) cells and other mammalian cells as production platforms. CHO cells are 
preferably used for protein production because of their innate ability to secrete human-like 
recombinant proteins with post-translational modification, resistance to viral infection and 
familiarity with drug regulators. However, despite huge progress made in engineering CHO 
cells for high volumetric productivity, expression of DTE proteins like recombinant lysosomal 
sulfatase represent one of the poorly understood proteins. Furthermore, there are growing 
interest in the use of microRNAs (miRNAs) to engineer CHO cells expressing DTE proteins 
to improve cell performance of relevant bioprocess phenotypes. Therefore, we sought to 
understand miRNA expression profiles in CHO cell lines stably expressing DTE lysosomal 
protein and examined the effect of microRNA-engineering of these cell lines on protein 
expression.  
Firstly, we utilized next generation sequencing (NGS) technology for an integrated mRNA and 
microRNA profiling of three CHO cell lines (including parental cell) stably expressing a DTE 
lysosomal protein cultivated in a biphasic fed-batch mode within a 5L Dasgip bioreactor. With 
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exception to the parental cell line, the other two cell lines differ by their productivity and were 
identified as low and high producers. Following RNA-seq and small RNA-seq data analyses 
by the Bioinformatics group at BioMarin, among other analyses, correlation and differential 
analyses identified 500 mRNA and 35 miRNAs that were differentially expressed in these cell 
lines over cultivation period. This study identified miRNAs that are potential targets for 
engineering of CHO cells for the enhancement of DTE protein expression. Secondly, in an 
independent study, we identified miR-23a and miR-377 as miRNAs targeting sulfatase 
modifying factor 1 (SUMF1) by using in silico prediction tools as SUMF1 is an activator of 
sulfatases. Transient inhibition of endogenous miR-23a/miR-377 significantly enhanced 
recombinant sulfatase enzyme specific activity in CHO cells without affecting cell growth. 
Though, inhibition of miR-23a/miR-377 had no significant effect on the mRNA and protein 
levels of SUMF1, overexpression of miR-23a/377 significantly reduced both the mRNA and 
protein levels of SUMF1. In summary, our data demonstrates the importance of using miRNA 
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  1.0 INTRODUCTION AND LITERATURE REVIEW 
The increase in production of more complex, difficult-to-express (DTE) recombinant 
therapeutic proteins e.g. multi-specific proteins, fusion proteins, membrane proteins, 
lysosomal enzymes and other DTE monoclonal antibodies (mAb) have seen difficulties in 
manufacturability using CHO cells or other mammalian cells as production factories (Kelly et 
al. 2014; Migani, Smales, and Bracewell 2017). Mammalian cells are preferably used for the 
production of most proteins because of their ability to produce proteins with human-like post-
translation modification (PTM), their resistance to viral infection and popularity with drug 
regulators. Lysosomal enzymes represent one of the least studied or reviewed recombinant 
therapeutic class of proteins compared to monoclonal antibodies (mAbs) and other well 
understood proteins manufactured as biologics. In the early years of lysosomal enzyme 
production as a biopharmaceutical, CHO cells production of lysosomal enzyme could be as 
low as 20,900 U/mg (~100 micrograms of enzyme/107 cells) produced, secreting ~ 13,000 U 
(or 75 µg/107 cells) per day (Ioannou, Bishop, and Desnick 1992). Of recent, the productivity 
yield has increased (e.g. 0.05-0.25 mg/mL of GAA production) as a result of advances in 
bioprocessing process parameter control, media formulation and genetic engineering (Migani, 
Smales, and Bracewell 2017). In spite of these advances the full potential of the mammalian 
host systems used in the production of DTE lysosomal proteins have not been completely 
utilized. At this time point, engineering of the mammalian host system might represent a viable 
route to increasing production yield of DTE lysosomal proteins. The lysosome which acts like 
the recycle warehouse of the cell, contains proteins that breakdown glycosaminoglycans 
(GAG) and other macromolecular substrates. Mutations in the gene coding for any of these 
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lysosomal enzymes or proteins can lead to the accumulation of these substrates in the 
lysosome leading to a disease state termed lysosomal storage disorder (LSD). An example 
of these diseases among others is multiple sulfatase deficiency (MSD) caused by mutations 
in sulfatase modifying factor (SUMF1), a gene that encodes formylglycine –generating 
enzyme (FGE). A difficult-to-express protein could arise as a result of insolubility, improper 
folding, aggregate formation (e.g. variable region of dimeric Fab antibody), and issues 
stemming from protein half-life, production yield and stability. In the world of rare diseases – 
lysosomal storage disorders (LSD), producing active form of lysosomal protein could 
sometimes pose a challenge to scientists 
The role of microRNA in cancer and autoimmune diseases is well researched unlike its 
application in bioprocessing for protein expression purposes. MicroRNAs (miRNAs) has been 
shown to play critical roles in many cellular processes – differentiation, development, cellular 
growth, apoptosis, including the expression of transcription factor EB (TFEB) that regulates a 
gene network called Coordinated Lysosomal Expression and Regulation (CLEAR) (de 
Queiroz et al. 2016). A handful of work has been done linking non-coding RNA to gene 
expression in lysosomal storage diseases (LSD). Generally, microRNAs can be located 
between exons or introns of the genome. They tend to destabilize or inhibit the translation of 
their mRNA target by imperfectly binding to the 3’ UTR of the mRNA target. MicroRNA effect 
on CHO cells that has been a subject of intense research currently and it has been observed 
that as CHO cells behavior defer by the kind of protein they express and/or clonal variation, 
miRNA expression profiles changes (Maccani et al. 2014). Diiferent methods have been 
developed for the identification of miRNA expression relative to protein expression: microRNA 
library screen, mRNA and miRNA microarray, next-generation sequencing (Inwood, 
Betenbaugh, and Shiloach 2018)  
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1.1 Bioprocessing - production of therapeutic proteins  
Recombinant therapeutic proteins are usually produced in large scale via a process called 
bioprocessing. Bioprocessing, in the context of protein production, entails the use of living 
organisms to produce recombinant therapeutic proteins – antibodies, fusion proteins, 
anticoagulants, growth factors, hormones, interferons, enzymes, vaccines. The protein 
production process involves multiple stages from selection of expression host system to the 
use bioreactors for production. The choice of expression host like mammalian cells (e.g., 
Chinese hamster ovary cell (CHO), human embryonic kidney cells (HEK), Escherichia coli, 
insect cells, yeast, hybridomas etc.) depends on: the type of biopharmaceutical product (e.g. 
membrane protein, glycosylated proteins), post-translation modification (PTM) requirement, 
ease of use, protein stability and solubility, timing, cost, and familiarity with regulators among 
others.  
 
1.2  MicroRNA  
MicroRNAs (miRNAs) are short non-coding ribonucleic acid (RNA) molecule, about 18-24 
nucleotide in length. They negatively regulate genes post-transcriptionally, regulating one-
third of the genes in eukaryotic cells without adding any translational burden on the cell 
machineries unlike protein coding genes when overexpressed. MiRNAs regulate genes by 
binding imperfectly (one or two base pair difference) to the 3' untranslated region (UTR) of 
their target mRNA with mismatches and bulges causing repression or a perfect binding 
causing degradation by the miRNA-induced silencing complex (miRISC) (Ha and Kim 2014). 
The 5' end of miRNA at nucleotide 2 to 8 contain a domain region called “seed region” for the 
recognition of target mRNA. Though in plants, microRNAs bind to their targets in a near-
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perfect manner inducing the cleavage of mRNA targets by endonuclease (Pasquinelli 2012). 
Though a rare example of near-perfect complementarity has been mentioned for animals in 
which miR-196 binds to HOXB8 mRNA (Pasquinelli 2012).  
One major feature of MicroRNAs is their known conservative characteristics across species, 
and even as similar target recognition seem to be conserved in mammalian cells (Friedman 
et al. 2009). MiRNAs can either be downregulated or overexpressed where alterations in their 
levels can cause changes in cell phenotypes. They have been described as molecules that 
fine tune gene expression in eukaryotic cells (Baek et al. 2008) and have been shown to play 
vital roles in cellular processes like differentiation, proliferation, development , and apoptosis. 
Alterations in the levels of miRNA has been linked to various diseases, in most cases cancer 
(Wang, Wei, and Sarkar 2012). These findings are prominent in cancer research for over two 
decades now and protein expression scientists are currently exploring ways to tap into the 
potentials of miRNAs as global gene regulators in the field of bioprocessing. Techniques like 
crosslinking and immunoprecipitation (CLIP) and ribosome profiling have been employed to 
understand miRNA binding sites and its targets (Pritchard, Cheng, and Tewari 2012). Different 
culture conditions (nutrient depletion, temperature shift) has been shown to cause changes in 
miRNAs levels in profiling studies in a bioprocessing system (Druz et al. 2013; N. Barron et 
al. 2011).  
For example, Strotbek et al (2013) were able to demonstrate that miR-557 and miR-1287 
improved growth profile (VCD) and specific productivity (qP) respectively in CHO cells 
expressing IgG1 proteins. The CHO cells engineered with these miRNAs exhibited higher 
IgG1 titer while retaining product quality. In addition, the CHO cells exhibited a much higher 
protein titer and specific productivity when the miRNAs were co-transfected (Strotbek et al. 
2013).  




1.2.1  MiRNA Biogenesis: 
MicroRNAs are transcribed by Polymerase II (Pol II) into a primary transcript (pri-miRNA) that 
is about 72 nucleotide in length inside the nucleus of the cell (Figure 1). Thereafter, it is 
processed by a microprocessor complex- Drosha and its cofactor DiGeorge syndrome critical 
region gene 8 (DGCR8 or Pasha), into a hairpin precursor microRNA (pre-miRNA) which is 
then transported into the cytoplasm by RanGTP-dependent exportin-5 (XPO5) protein. While 
in the cytoplasm, the loop of the pre-miRNA is removed by DICER/Tar RNA binding protein 
(TRBP) complex forming a microRNA duplex- guide and passenger (or star) strands that is 
21-24 nucleotide long. The resulting microRNA duplex is later bound by argonaute protein 
forming the miRNA-induced silencing complex (miRISC), includes GW182 proteins, which is 
directed by the guide strand to mRNA target for regulation. The star strand (miRNA*) is 
degraded and the guide strand binds to the target mRNA through partial complementarity with 
bulges resulting in repression of translational initiation or cleavage of the target mRNA in some 
rare occasion of near perfect complementarity e.g., miR-196 targeting HOXB8 mRNA 
(Pasquinelli 2012). The selection of the strand destined for degradation is dependent on the 
thermodynamic stability of the 5’ end (Pasquinelli 2012; O’Brien et al. 2018; Ha and Kim 2014).  




Figure 1: Canonical pathway of microRNA biogenesis. Image used and adapted from Winter et al. 
(2009)(Winter et al. 2009) 
 
1.2.2  Mechanism of action 
The effect of synthetic microRNA inhibitors on cell physiology is dependent on abundance of 
endogenous microRNA expression it is inhibiting. MicroRNA recognizes its target by binding 
to the 3’ UTR of the mRNA target. Though there are reports that revealed binding to the 
mRNA target at the 5’ UTR (J. Robin Lytle, Therese A. Yario 2000), protein coding region, 
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and 3’ UTR. Though there are reports that miRNAs can also upregulate the expression of 
their target genes as against their nominal function of negatively inhibit gene expression 
(Vasudevan 2012).  
1.2.3 Methods of engineering mammalian cells using miRNA 
In most cases, transient transfection of microRNA mimics or inhibitors into mammalian cells 
is performed by lipid-mediated transfection method. To efficiently assess transfection 
efficiency of the transfection reagent used it is pertinent to assess the effect of the miRNA 
mimic or inhibitor on their target mRNA/protein in addition to using flow cytometry or 
fluorescence microscopy. The reason is that using flow cytometry or florescence microscopy 
alone could give a false positive result because the transfected microRNAs could be stalked 
in the endosome, firmly bound with the transfection reagent and not being released in order 
to be bound with the miRISC complex for mRNA targeting (Fischer et al. 2013). Interestingly, 
assessing transfection efficiency by measuring the levels of miRNA mimics using qRT-PCR 
might not really portray the accurate amount of functional or active miRNAs bound to 
Argonaute protein, while microRNA inhibitors could inhibit qPCR reaction. Using qRT-PCR 
alone might only be measuring the amount of both vesicular (inactive) and Argonaute-bound 
(active) mimics (Thomson et al. 2013). Thomson et al. 2013 used Argonaute:miRNA 
immunoprecipitation assay to accurately assess functional or active microRNAs post transient 
transfection of microRNA mimics. 
1.2.3.1  mRNA and miRNA profiling of CHO cells 
To generate a better understanding of the transcriptome (mRNA or miRNA) of CHO cells, 
scientists are using high throughput technologies (e.g. next-generation sequencing, 
microarray technology, liquid chromatography/mass spectrometry (LC/MS) and miRNA 
library) in combination with cell cultivation (suspension or static) and different cell culture 
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modes (fed-batch, batch or steady state)(Table 2). Only of recent was the CHO genome was 
sequenced providing more opportunities to understand the biology of this important host cell. 
Profiling of CHO cells using these technologies have providing much characterization of CHO 
cell lines and context for cell engineering purposes. Although, these profiling techniques have 
their advantages and disadvantages (Table 1) (Pritchard, Cheng, and Tewari 2012)  
Table 1: Advantages and disadvantages of miRNA profiling technologies and their 
commercially available platforms*  
MiRNA Profiling 
Technologies 
Advantages Disadvantages Platforms 
MicroRNA microarray  Low cost and high throughput 
 Affordable 
 
 Lower specificity compared to 
qRT-PCR or RNA sequencing 
 Cross hybridization between 
probes and sample 
 No detection of novel miRNAs 
Genome Biochip miRNA, 
GeneChip miRNA array, 
GenoExplorer, MicroRNA 
microarray, miRCURY LNA 
microRNA array, OneArray, 
uParaFlo biochip array 
RNA sequencing   No cross hybridization 
between samples 
 Higher sensitivity detecting 
very less abundant genes 
(Stiefel et al. 2016)  
 Broader dynamic range. Can 
detect novel miRNAs 
 
 Required expertise for 
computational analyses of data 
 Cannot be used for absolute 
quantification 
HTS: HiSeq 2000, SOLiD, 
GS FLX+ (454 
sequencing) 
Small-scale: Ion Torrent, 
MiSeq, GS Junior (454) 
qRT-PCR  No cross hybridization 
between samples 
 High sensitivity and specificity 
 Can be used for absolute 
quantification  
 
 Cannot identify novel miRNAs 
 Medium throughput with 
respect to number of samples 
processed per day 
 
Taqman individual 
assays, miRCURY LNA 
qPCR, TaqMan TLDA 
microfluidics card, 
Biomark HD system, 
SmartChip human 
microRNA, miScript 
miRNA PCR array 
   *Table modified from Pritchard, Cheng and Tewari (Pritchard, Cheng, and Tewari 2012) 
 
   




Table 2: mRNA and miRNA profiling experiment conducted on CHO cell host platforms 
Profiling 
Technique 








CHO-DG44 Suspension   Human serum 
albumin (HSA) or 
mAb IgG1 













with 10% FBS 


























CHO-K1 Suspension IgG1 Batch (Bort et al. 2012) 






















Epo-Fc nil (Klanert et al. 
2016) 







CHO-DG44 Suspension mAb Fed-batch  (Stiefel et al. 
2016) 
 
1.2.4  MicroRNA-engineering of CHO cells  
Mammalian cells are the preferred choice of cell factories for the manufacturing of biologics 
because of their ability to make proteins with similar posttranslational modifications (PTM) to 
that of humans unlike bacteria and yeast cells. However, mammalian cell factories or 
expression systems still grapple with the hurdle of an optimal protein yield. In addition, due to 
the growing demands of biologics and incremental development of new technologies scientist 
testing boundaries searching for more ways to optimize mammalian cells most especially 
CHO cells. Subsequently, different approaches like cellular engineering, process engineering 
(Alves et al. 2015), media optimization and genetic engineering have applied to CHO cells to 
optimize productivity. Common trend in genetic approach is the overexpression of a gene of 
interest which invariably adds more translational burden to the cell machinery. There are 
growing interest among the scientific community of using miRNA to engineer CHO cells since 
this approach do not add extra translational burden and the actions of one miRNA could have 
effect on more than one pathways. Engineering CHO cells with miRNAs have been applied in 
to improve different cellular processes such as apoptosis (Druz et al. 2013), protein production 
(Loh, Yang, and Lam 2017; Chen et al. 2005; Fischer, Paul, et al. 2015; Kelly et al. 2015; 
Meyer et al. 2017; Emmerling et al. 2016; Loh et al. 2014), growth rate (N. Barron et al. 2011) 
1.2.4.1  MicroRNA engineering of CHO cells expressing difficult-to-express (DTE) protein  
Proteins are said to be difficult-to-express (DTE) if they are insoluble making it difficult for 
downstream characterization and analyses e.g. Western blotting and purification. Improper 
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folding (or misfolding) of proteins as well as aggregate formation could be troubling when 
using producing these proteins especially for commercial purposes. The fusion of human 
serum albumin (HSA) or Fc to the N-terminus of DTE protein helped I mitigating insolubility 
(Carter et al. 2010). Co-expression of molecular chaperones (BiP, PDI, CypB), unfolding 
protein response (UPR) and chemical chaperones (PBA, DMSO, glycerol) have been used to 
mitigate aggregation problems (Johari et al. 2015). Moreover, in the case of enzymes, most 
of it could exist in their inactive form. Lastly, expressing a low yield protein is one of the most 
common problems and scientists are using cellular and process engineering methods to solve 
this problem. Previous studies have shown that CHO-K1 has a larger ER and higher 
mitochondrial mass than CHO DUXB11 which might indicate reason why CHO-K1 gives better 
yield.  
Of recent, scientists are using miRNA to engineer CHO cells secreting DTE proteins (e.g. 
lysosomal proteins, membrane proteins- neurotensin receptor type 1 (NTSR1) and serotonin 
transporter (SERT) in order to improve relevant bioprocess phenotypes like productivity 
(Inwood, Betenbaugh, and Shiloach 2018; Pybus et al. 2014; Schoellhorn et al. 2017; Fischer 
et al. 2017, 2013).  
1.3  Difficult-to-express lysosomal enzymes 
Lysosomal enzymes are proteins in the lysosome of most eukaryotic cells and are responsible 
for the breakdown of cell waste products, carbohydrates, lipids, proteins, nucleic acids which 
are then returned to the cytoplasm. They are produced in the endoplasmic reticulum and 
modified in the Golgi apparatus. The enzymes are destined for the lysosome since they are 
tagged with mannose-6-phosphate (m6PO4) which binds with mannose-6-phosphate 
receptors which directs the enzyme to the lysosome with aid of other mechanisms. Though 
some of the enzyme may not require m6PO4 receptor for trafficking reason why β-
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glucoerebrosidase had its mannose terminated and successfully produced in CHO cells 
(Desnick and Schuchman 2012). Deficiency in these enzymes can cause the accumulation of 
their substrate in the lysosome of the cells leading to conditions known as lysosomal storage 
disorder (LSD).  
Since prokaryotic cells do not execute post-translational modification (PTM) of proteins, CHO 
or other mammalian cells have become the host platform of choice in the manufacturing of 
lysosomal enzymes. Lysosomal enzymes require PTM for their stability and activity. 
Production of lysosomal enzyme could be difficult as it has been reported that not all 
overexpressed recombinant enzyme in a CHO host are successfully secreted into the 
surrounding culture medium. Consequently, production of a large batch will be required 
leading to a high cost of production (Ioannou, Bishop, and Desnick 1992; Desnick and 
Schuchman 2012). Examples of lysosomal enzymes are: glycosidases, protease, sulfatases, 
acid phosphatases and lipases etc. 
Aim and scope of research 
Though CHO cells have been the commonly used mammalian cell line for the production of 
recombinant therapeutic protein scientists still believe that the production capacity limit of this 
workhorse has not been reached. Different cellular, process and genetic engineering means 
has been used to make this happen. Currently, protein expression scientists are tapping much 
of the knowledge of miRNA garnered from cancer research and applying that to CHO or other 
mammalian cell engineering to induce relevant bioprocess phenotypes. One key factor that 
really promoted this research was the sequencing of the CHO genome, which promoted 
profiling and cellular engineering of different CHO cell lines. The advantage of using miRNA 
over gene expression for engineering purpose is that it does not add an extra translational 
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burden to the machineries of the cell. The scope of this research will rest on the profiling and 
miRNA-engineering of CHO cell line stably expressing a DTE lysosomal enzyme.  
Significance of research 
The miRNAs and mRNA identified from the next-generation sequencing experiment of CHO 
cell lines expressing DTE lysosomal enzymes will provide the scientific community potential 
list of targets for cell engineering for the improvement of cell growth and volumetric 
productivity.  In addition, it provided substantial knowledge of miRNA dynamic changes in 
CHO cell lines that vary in their growth rate and specific productivity.  
Furthermore, identifying sulfatase modifying factor 1 (SUMF1) as a target to miR-23a-3p and 
miR-377-3p and observing an improvement in sulfatase activity by inhibiting these miRNAs 
demonstrate the importance of using miRNA to effect desirable bioprocess qualities in CHO 
cells. This observation could provide a context for research of these miRNAs in clinical 
research 
Overview of the study 
This thesis is written in chapters. Chapter 1 has the introduction and literature review. It consist 
of overview on bioprocessing, microRNA, its origin, mechanisms of action and its application 
in engineering difficult-to-express proteins. Lastly it contains the aim, scope and significance 
of the research 
Chapter 2 highlights the hypothesis and objective of the research. Chapter 3 contains full 
description of the materials and methods. Chapter 4 and Chapter 5 contain miRNA/mRNA 
profiling research and miRNA engineering experiment respectively. 
 







2.0  RESEARCH OBJECTIVES 
 
Hypothesis 
MiRNA has been proven through research to have the ability to regulate major cellular 
processes in the cells that are relevant to bioprocessing phenotypes of CHO cells as 
production host. Developing a good understanding of miRNA expression dynamics will 
help in identifying selected miRNAs as engineering targets whose impact on CHO cell 




1. Identify potential miRNAs as targets for downstream CHO cell engineering by 
transcriptomic profiling of in house CHO cell stably secreting a difficult-to-express (DTE) 
enzyme 
2. Identify potential miRNAs that targets sulfatase modifying factor 1 (SUMF1) and 
evaluate their effect on sulfatase specific activity 
 
 




3.0  MATERIALS AND METHODS 
3.1 CELL CULTURE TECHNIQUES AND TRANSFECTION  
3.1.1 Biosafety cabinet 
Cell culture work were performed in a Logic+ laminar flow biosafety level II cabinet (Labconco, 
G3371028) to prevent contamination from airborne particulates. Before any cell culture work, 
the work area inside the cabinet was wiped down with 70% isopropyl alcohol (IPA). All media 
bottles and cell culture flasks were all wiped down with IPA to prevent transferring 
contaminants into the cabinet. At the end of all cell culture work, the cabinet was wiped down 
again with IPA and sash closed. 
3.1.2 Cell Thawing 
The frozen cells were retrieved from liquid nitrogen and thawed using a liquid water bath (Lab 
Armor) with gentle swirling or the use of ThawStar thawing system (Biocision). The thawed 
cells were pipetted and transferred to a T-75 flasks containing 10 mL of media pre-warmed at 
37⁰ C. Flask was transferred to a static incubator kept at a temperature of 37⁰ C, 5% CO2 and 
8% humidity for 24 hours. The cells were pelleted by centrifugation at 250 x g for 5 minutes 
and re-suspended in a fresh media for subsequent culturing in order to remove traces of 
DMSO contained in cell freezing media.  
3.1.3 Cell Freezing  
Cells for cryopreservation were counted and harvested when the cell concentration was at 
about 4.0e6 cells/mL of the exponential cell growth phase. The cells were pelleted by 
centrifugation at 250 x g for 5 minutes and supernatant discarded. 1 mL of cryopreservation 
media was added to re-suspend every 10e6 cells pelleted. 1 mL of the mixture containing 
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10e6 cells was transferred to a cryovial and stored at -80⁰ C overnight. It was transferred the 
following day to a liquid nitrogen kept at -180⁰ C for long term storage. 
3.2 Passaging of cell lines  
3.2.1 Adherent cells 
Cell splitting were done at a ratio of 1:2 when the cells have reached confluency of 80-90%. 
Before splitting, spent media was removed with a glass pipette or aspirated before rinsing with 
sterile 1X DPBS (Corning, 21-031CV) to remove any residual phenol contained in the media 
that will dampen the effect of TrypLE Express (ThermoFisher Scientific, 12605-028), for cell 
dissociation. After the addition of 2-5 mL TryPLE Express, the flask or plate was transferred 
to a humidified HERAcell Vios 160i (Thermo Scientific) static incubator kept at 5% CO2 and 
37⁰ C for 2-4 minutes. The flask was observed under the Evos XL core microscope (Life 
Technologies) to make sure all cells have dissociated and assumed a circular morphology. 
About 3 - 20 mL serum-containing media were added into flask to keep the cells in suspension 
and pipetted out into a 15 or 50 ml tube depending on the size of the flask. These tubes were 
then centrifuged at 250 g for 5 minutes. After centrifugation, the supernatant was discarded 
and the cell pellet re-suspended in a fresh serum-containing media. 20 mL fresh media was 
used for cells split equally into two T-75 flask (Corning) and 30 ml media for cells split equally 
into two T-175 flask (Corning).  
3.2.2 Suspension cells 
Cells to be passaged were first counted on the ViCell™ XR (Beckman Coulter) to obtain viable 
cell density and viability values. Cells were passaged every 3-4 days at a seeding density of 
0.5 x 106 cells/mL. The volume of cell culture required to seed cells were aliquoted into a new 
flask and fresh pre-warmed (37⁰ C) media was added at the required volume. The flask was 
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transferred to a stackable incubation shaker (Multitron Pro, Infors HT) maintained at 37⁰ C in 
atmospheric CO2 of 5% and 80% humidity for 3-4 days with 125 rpm rotation before 
passaging. 
3.2.3 Cell counting  
3.2.3.1 Vicell™ XR cell viability analyzer 
500 uL of cell culture from cells grown in flask was aliquoted into a sampling cup and inserted 
into the ViCell™ XR (Beckman Coulter) sample cup holder for determination of the 
concentration of cells, viability and cell size. The ViCell uses the Trypan Blue exclusion 
principle by counting cells stained with dye as dead cells.  
3.2.3.2 Nucleocounter NC-200  
Cell culture sample from cells grown in 6-well plates was loaded into vial cassette 
(Chemometec, 941-0011) by dipping the sterile cassette tip into the well containing 
suspended cells and pressing the piston to aliquot sample (~1.4ul used) into the cassette. 
The undulating shape of the mixing channel in the cassette allows the sample to mix very well 
with acridine orange and DAPI dyes contained in this channel. The acridine dye stains all 
cells, while DAPI stains all non-viable cells. After aliquoting the cell sample, the cassette was 
inserted into the NC-200 cassette holder and sample analyzed by pressing the “run” button.  
3.3 Transfection  
3.3.1 Transfection of siRNA/microRNAs with lipid-base reagent method 
Transient transfection of suspension cells were carried out by seeding and transfecting the 
cells on the same day (reverse transfection). For adherent cells, the cells were seeded 24 
hours before transfection (forward transfection). Following manufacturer’s protocol, 
DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD
18 
 
transfection of suspension cells (e.g. CHO or HEK293 cells), were carried out on the day of 
transfection by seeding 2.5 mL of cell culture at a concentration of 0.3 - 0.8e6 cells/mL 
(depending on what cell line was used) in each required well of a 6-well plate. Transfections 
were carried out in duplicates. All components required for transfection were used in 5-10% 
excess to compensate for loses due to pipetting. A master mix of microRNA mimic/inhibitor 
or siRNA was created by diluting 7.5 uL of miRNA mimic/inhibitor or siRNA (20μM) with 485 
uL of Opti-MEM I reduced serum media (Gibco, 31985070) in a 5 mL DNA Lobind tube 
(Eppendorf, 0030108310). The mixture was mixed gently. Lipofectamine TM RNAiMax 
(Thermo Scientific, 13778150) reagent was mixed gently before use. 7.5 uL of Lipofectamine 
RNAiMAX were added to the tube containing mixture of miRNA mimic/inhibitor or siRNA and 
Opti-MEM I reduced serum media for complex formation. The mixture was allowed to incubate 
for 10-20 minutes at room temperature. After incubation, 500 uL from the mixture was added 
to each well containing 2.5 mL of 0.3-0.6e6 cells/mL of cells giving a final volume of 3 mL and 
final concentration of 50 nM. Each 6-well plate was mixed gently by rocking back and forth. 
Plates were kept in a static incubator for 96 hours.  
3.3.2 Transfection of plasmid DNA (pDNA) using electroporation method 
Transient transfection was carried out by using Maxcyte STX scalable transfection system 
(MaxCyte) for adherent or suspension cells. Adherent cells were trypsinized with TrypLE 
Express (Thermo Scientific, 12605-028) and neutralized with cell media and mixture 
transferred to a 15 mL tube.  However, for suspension cells, the cells were transferred directly 
to a 15 mL tube. With a target cell culture volume of 30 mL, 20e6 cells in suspension were 
spun at 250 x g for 5 minutes and supernatant discarded. Cell pellet was rinsed in 1.5 mL of 
electroporation buffer (Maxcyte, B201-100) and pelleted again at 250 x g for 5 minutes. While 
the cells were being spun, 20 μg of pDNA was aliquoted into a 1.5 mL microcentrifuge tube 
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and the OC 400 processing assemblies (PA) were labeled based on experimental design. The 
cell pellet were dissolved in the right volume of electroporation buffer (400 uL less volume of 
plasmid used) and mixed with the plasmid by gentle up and down pipetting. The mixture were 
transferred to a PA in a final volume of 400 uL avoiding the generation of air bubbles and 
made sure the liquid was in full contact with both sides of the PA. The PA were inserted into 
the Maxcyte STX system and the cell transfection protocol was selected depending on what 
cell line was used. After electroporation, the PA was removed from the STX system and the 
electroporated cells were transferred to an empty 30 mL Ehrlenmeyer flask (Corning). 5ml of 
required cell culture media was added to the 400ul electroporated cells contained in the 30ml 
flask and incubated in a static incubator at 37⁰ C for 20 - 30 minutes. After incubation, 24.6 
uL of additional media was added to the flask, which brought the cell density to about 0.3 – 
0.6e6 cells/mL. Cells were cultured either in a 6-well plate or cell culture flask.  
3.3.3 Cell Imaging/Transfection efficiency measurement 
Green fluorescent protein (GFP) plasmid and small-interfering RNA (siRNA) Block-iT Alexa 
Fluor 555 red fluorescent control were used as indicators to assess transfection efficiency in 
a lipid-mediated or electroporation transfection method. Media from the well of a 6-well plate 
containing cells transfected with GFP or Alexa Fluor were aspirated and about 1 mL of 1X 
DPBS was added in order to eliminate any color background generated by the media when 
viewed under the EVOS FL Auto fluorescence microscope (Life Technologies). The cells 
transfected with GFP or Red Alexa Fluor were viewed under the fluorescent channel for GFP 
or Texas Red (RFP) respectively. The images obtained were viewed under 10X, 20X or 40X 
magnification.  
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3.4 MOLECULAR BIOLOGY TECHNIQUES 
3.4.1 Molecular biology water  
Water for preparing solutions used for assays were made using ultrapure water. The ultrapure 
was generated from Milli-Q-Advantage A10 water purification system (Millipore). Hypure 
molecular biology grade water (GE, SH30538.01) was used for reconstituting or rehydrating 
antibodies and oligonucleotides. 
3.4.2 Sterilization  
Glassware used for solution preparation were washed and cleaned by laboratory operation 
unit at BioMarin. Other materials for cell culture and molecular biology were washed with 
Tergazyme (Alconox), a detergent containing protease enzyme, and rinsed with tap water. 
Microcentrifuge tubes placed in a cylindrical plastic container with lid were sterilized by 
autoclaving at 121⁰ C for 45 minutes under a pressure of 1 bar by lab operation personnel. 
3.4.3 Reconstitution of lyophilized miRNA  
Lyophilized MicroRNAs were reconstituted by the addition of nuclease-free molecular water 
(GE healthcare LifeSciences, SH30538.01) to a final stock concentration of 20 or 100 μM. 
After the addition of nuclease-free water, mixing was done by up and down pipetting. The 
mixture was allowed to incubate for 10 minutes at room temperature before being transferred 
to -20⁰ C for storage.  
3.4.4 Rehydration of antibodies 
Primary and secondary antibodies for Western Blotting were rehydrated by the addition of 
certain amount 1X DPBS to a concentration recommended by the supplier of the antibodies. 
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After addition of 1X DPBS, mixing was done by up and down pipetting followed by 
centrifugation at 250 x g for 30 seconds. 
3.4.5 Extraction of total RNA (including small RNA - microRNA) 
Total RNA, including small RNA, was extracted using Quick-RNA Microprep (Zymo Research, 
R1050). Samples of suspension cells were pelleted at 250 x g for 5 minutes in a minicentrifuge 
(Eppendorf) and supernatant discarded. For adherent cells, the cells were dissociated with 
TrypLE Express (Thermo, 12605028) and pelleted as described above. For both adherent 
and suspension cells, the cell pellets were resuspended in 200 – 400 uL of RNA lysis buffer 
and vortexed briefly for homogenization. Particulates were removed by centrifuging the 
lysates at 14000 x g for 1 minute. To purify the RNA, the supernatant was transferred to an 
RNase-free tube and 100% ethanol added to the lysis buffer containing the sample at a ratio 
of 1:1. Reaction mixture was well mixed by up and down pipetting. The mixture was 
transferred to a Zymo-Spin IC column enclosed in a 2 mL collection tube and centrifuged at 
14000 x g for 30 seconds. The flow-through was discarded. For trace DNA removal, the 
column was washed with 400 uL of RNA wash buffer and centrifuged at 14000 x g for 30 
seconds. The flow-through was discarded. DNase I reaction mixture was prepared using 
DNase I and DNA digestion buffer at a ratio of 1:7 respectively. 40 uL of DNase I reaction 
mixture was added into the spin column directly, incubated at room temperature for 15 
minutes and then centrifuged at 14000 x g for 30 seconds. 400 uL of RNA prep buffer was 
added to the column, centrifuged at 14000 x g for 30 seconds and flow-through discarded. 
The column was washed with 700 uL RNA wash buffer, centrifuged at 14000 x g for 30 
seconds and flow through discarded. 400 uL of wash buffer was added to the column and 
spun at 14000 x g for 2 minutes to completely remove residual wash buffer in the column. The 
column was transferred to a new 1.5 mL tube (Eppendorf) and 40 uL of DNase/RNase-free 
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water was added into the column and centrifuged at 14000 x g for 30 seconds for RNA elution. 
The eluted RNA was stored at 80⁰ C.  
3.4.6 Determination of nucleic acid concentration  
Quantification of double stranded DNA (dsDNA) or single stranded RNA (ssRNA) 
concentration was carried out using DS-11 spectrophotometer (Denovix) by following 
manufacturer’s protocol.  
3.4.6.1 Plasmid DNA 
The dsDNA icon was first tapped. This led to the opening of the dsDNA measurement window. 
The top and bottom sample surfaces of the DS-11 spectrophotometer (Denovix) was wiped 
down with a dry lab wipe and 2 uL of nuclease-free water (Qiagen) was pipetted on the sample 
surface as blank measurement. The top arm was lowered and the “blank” button tapped. After 
blank measurement, the sample surface was wiped down with fresh dry lab wipe. 2 uL of test 
sample (dsDNA) solution was pipetted onto sample surface, sample name entered, arm 
lowered and the “measure” button tapped to obtain absorbance value. The measurement 
generates DNA concentration in ng/μL including the 260/280 and 260/230 absorbance values. 
The result was exported through the instrument email messaging system.  
3.4.6.2 Total RNA 
The same protocol was followed as illustrated above for dsDNA except that RNA icon was 
tapped for measurement of RNA absorbance values.  
3.4.7 Determination of RNA quantity and quality using Bioanalyzer 
Total RNA concentration and quality were determined on the Agilent 2100 Bioanalyzer 
instrument using the RNA 6000 Nano Kit (Agilent, 5067-1511) according to the instruction of 
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the manufacturer. During sample preparation, total RNA isolated was diluted to 100 ng/µL 
because the quantitative range for analysis on the instrument falls between 25 – 500 ng/µL. 
Before each measurement on the Agilent 2100 Bioanalyzer instrument, RNaseZAP (Ambion, 
9780) and RNase-free water was used for routine decontamination and cleaning of the 
electrode respectively. In preparing the gel, 550 μL of RNA gel matrix was pipetted into a spin 
filter and centrifuged at 1700 x g for 10 minutes at room temperature, aliquoting 65 μL into a 
microcentrifuge tube. The gel-dye matrix was prepared by equilibrating the RNA dye 
concentrate to room temperature for 30 minutes. The dye was vortexed for 10 seconds, spun 
down and 1 μL of the dye was added to the tube containing 65 μL aliquot of filtered gel. The 
mixture was vortexed and spun in a minicentrifuge at 13000 x g for 10 minutes at room 
temperature. After placing the RNA chip on the chip priming station (CPS), 9 μL of the gel-
dye mix was pipetted into a well marked . Ensuring that the plunger was positioned at 1 
mL level, the CPS was closed, plunger pressed down until it was held by the clip and waited 
for 30 seconds before releasing the clip. After 5 seconds, the plunger was pulled to the 1 mL 
position. The CPS was opened and 9 µL of the gel-dye mix was pipetted into wells marked
. The unused gel-dye mix was discarded. 5 µL of RNA marker was pipetted into all 12 
sample wells and in the well marked with a ladder sign. In addition, 1 µL of each RNA sample 
was pipetted into the sample wells depending on the number of RNA sample being analyzed. 
1 µL of the RNA marker was pipetted into each unused sample well. The chip was placed 
unto an IKA vortex mixer horizontally and vortexed at 2400 rpm for 1 minute. Finally, within 5 
minutes the chip was ran on the Agilent 2100 Bioanalyzer instrument to obtain the RNA 
concentration and RNA integrity number (RIN). The RIN gives an estimate of the quality of 
the RNA and it ranges from 1 – 10, with 10 being the best quality.  
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3.4.8 Reverse transcription (cDNA generation) 
Reverse transcription experiment was carried out using miScript II RT Kit (Qiagen, 218160) 
for the generation of complementary DNA (cDNA) following instructions from the 
manufacturer. Total RNA, containing miRNA, was used as a template. RNA sample stored in 
-80⁰ C was thawed in ice, while 10X miScript Nucleic Mix and 5X miScript HiSpec Buffer were 
thawed at room temperature and later placed on ice. In order to synthesize first-strand cDNA, 
reverse-transcription master mix was prepared in a microcentrifuge tube for each RNA sample 
by adding 4 µL HiSpec buffer, 2 µL Nucleic mix, 2 µL miScript Reverse Transcriptase Mix, 
RNase-free water (amount depends on RNA template amount used) and finally RNA sample 
(amount used depends on RNA sample concentration used which falls at the upper limit of 10 
ng – 2 µg) for total mixture of 20 µL. The master mix was mixed gently, centrifuged and placed 
on ice. The tube containing master mix was incubated in a thermal cycler (Life Technologies) 
at 37⁰ C for 60 minutes, then at 95⁰ C for 5 minutes in order to inactivate miScript Reverse 
Transcriptase Mix. Tube was later placed on ice. The 20 µL reaction mixture was diluted by 
adding 200 µL of RNase-free water, mixed gently and centrifuged. This ensured that cDNA 
generated fell between 50 pg – 3 ng per PCR. The diluted cDNA was either used immediately 
for real-time PCR or the undiluted cDNA was stored at -20⁰ C for future real-time PCR 
experiment.  
3.4.9 Real Time-PCR (qPCR) 
The real-time PCR (qPCR) was carried out using a miScript SYBR Green PCR Kit (Qiagen, 
218073) with miScript Primer Assay according to the protocol of the manufacturer for the 
detection of mature miRNA. All the content of each reagent: 2X QuantiTect SYBR Green PCR 
Master Mix, 10X miScript Universal Reverse Primer, and diluted cDNA was thawed, mixed 
and centrifuged before use. A reaction master mix was prepared according to Table 1. 
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Table 3: Reaction master mix for the detection of matured miRNA in a 384-well plate 
Component Volume/reaction 
(384-well) 
2x QuantiTect SYBR Green PCR Master Mix 5 µL 
10x miScript Universal Reverse Primer 1 µL 
10x miScript Primer Assay (U6 snoRNA, GAPDH, miRNA of 
interest) 
1 µL 
RNase-free water 2 µL 
cDNA Template (not added in master mix) 1 µL 
Total volume 10 µL 
The GAPDH and U6 SnoRNA forward primers were used for normalization of gene expression 
and mature miRNA expression levels respectively. The reaction master mix was prepared for 
three technical replicates with extra 10% reaction component used to compensate for loses 
due to pipetting. 1 µL of the cDNA template was dispensed into individual wells of the PCR 
plate for each replicate. The reaction master mix was mixed thoroughly and 9 µL dispensed 
into wells containing cDNA. The plate was tightly sealed with a film and centrifuged at 1000 x 
g for 1 minute at room temperature. The real-time LightCycler 480 (Roche Diagnostics) was 
programed according to the shown below. In addition, melting curve analysis was done to 
verify specificity (primer-dimer).  
Table 4: Roche LightCycler 480 cycling conditions 
Step Time  Temperature 
Activation step 15 min 95⁰ C 
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3-step cycling:   
Denaturation 15 s 94⁰ C 
Annealing 30 s 55⁰ C 
Extension 30 s 70⁰ C 
Cycle number 45 cycles  
The plate was placed in the real-time cycler and program started. The C(T) method 
(Schmittgen and Livak 2008) was used to calculate relative expression differences.  
3.4.10 Molecular cloning 
3.4.10.1 Agarose gel preparation 
In order to make 500 mL of agarose gel, 5g of Seakem LE Agarose (Lonza, 50004) was 
measured and poured into an amber bottle followed by the addition of 300 mL of TAE 1X 
buffer. The amber bottle with mixture was heated up in a microwave for at least 2 minutes to 
dissolve the agarose powder. 50 μL of 1X of Biotium gel green nucleic acid stain was added 
into bottle and mixed by gentle swirling. The bottle containing freshly prepared agarose gel 
was kept at 65⁰ C in a bead bath (Lab Amor).  
3.4.10.2  Gel extraction 
This process was carried out using the QIAquick Gel Extraction Kit (Qiagen, 28704) by 
following the procedures stated by the manufacturer. DNA was purified from small piece of 
gel that contained our desired DNA. Gel slice containing desired DNA was cut from agarose 
gel with a scalpel and transferred into a 1.5 mL microcentrifuge tube. The gel slice was 
weighed to accommodate the maximum amount (400 mg) the spin column could hold. Buffer 
QG was added to the tube with gel at a volume of 3:1 (100 mg gel ~ 100 μL). Gel was 
DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD
27 
 
incubated at 60⁰ C and vortexed every 2 minutes until gel slice dissolved completely. The gel 
sample was transferred to a MinElute spin column placed inside a 2 mL collection tube and 
centrifuged at 17900 x g for 1 minute at room temperature. The flow-through was discarded 
and process repeated if sample was greater than 800 μL. 500 μL of Buffer QG was added to 
the column and centrifuged at 17900 x g for 1 minute at room temperature. The flow-through 
was discarded and column placed back into the collection tube. Similar process as above was 
repeated using 750 μL of Buffer PE; however, the column was allowed to incubate for 3 minute 
after adding Buffer PE if DNA was intended for sequencing or blunt-ended ligation 
downstream. After discarding the flow-through to completely remove residual ethanol, the 
column contained in 2 mL collection tube was centrifuged at 17900 x g for 1 minute at room 
temperature. Column was placed in a new 1.5 mL microcentrifuge tube and 10 μL Buffer EB 
added to the center of the column membrane. To elute the DNA, the column was allowed to 
stand for 1 minute and centrifuged at 17900 x g for 1 minute at room temperature.  
3.4.10.3 PCR purification  
For the purification of PCR products, QIAquick PCR Purification Kit (Qiagen, 28104) was used 
according to specifications by the manufacturer. 5 volumes of Buffer PB was added to 1 
volume of the PCR reaction and mixed gently. The sample was transferred to a QIAquick 
column placed in a 2 mL collection tube and centrifuged at 17900 x g for 60 seconds at room 
temperature. After discarding the flow-through, 750 μL of wash Buffer PE was added and 
centrifuged at 17900 x g for 60 seconds at room temperature. In order to remove residual 
wash buffer, the column in 2 mL collection tube was centrifuged again for 1 minute at same 
conditions. After placing the column in a new 1.5 mL microcentrifuge tube, 30 μL of Buffer EB 
was added to the center of column, allowed to stand for 1 minute and centrifuged at 17900 x 
g for 1 minute at room temperature in order to elute DNA.  
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3.4.10.4 Plasmid DNA purification (maxiprep) 
Automated maxiprep purification of plasmid DNA was carried out using the BenchPro 2100 
Maxicard Plasmid Purification Instrument (Life Technologies) according to the purification 
protocols of the manufacturer. The instrument and air compressor was turned on and made 
sure that the air compressor wasn’t letting out air. Setup button was tapped to set up the 
instrument for maxiprep purification. The reagent tray foil was pierced with a piercing tool and 
an empty 2 mL collection tube with cap removed was placed into the elution tube slot. After 
opening the drawer of the instrument, the waste tray was removed and reagent tray placed in 
the waste tray slot ensuring the tray aligned with the slot. A cell liner was placed in the waste 
tray reservoir slot. The drawer was opened and waste tray containing reagent tray was placed 
into the waste tray slot. About 125 mL of E. coli culture was poured into the cell liner contained 
in the reservoir and covered with a lid. The drawer was closed gently which was followed with 
the insertion of the Maxiprep Card into a slot in the BenchPro 2100 instrument. The start 
button was tapped, following by the click of the run button in order to run the protocol. At the 
completion of the run, the card was removed from the slot and discarded. The drawer unit 
was opened to remove the elution tube containing purified plasmid DNA. The tube was 
capped and stored at -20⁰ C. The reagent tray and cell liner were discarded appropriately and 
the waste tray decontaminated with bleach and washed with detergent for future use.  
3.4.10.5 Transformation  
2 µL ligation reaction was added into vial containing One Shot TOP10 chemically competent 
E. coli and gently mixed. This was incubated on ice for 20 minutes. The cells in the vial was 
heat-shocked at 42⁰ C for 30 seconds and transferred immediately to ice. 250 µL of super 
optimal broth with catabolite repression (S.O.C) medium kept at room temperature was added 
into each vial and incubated at 37⁰ C for 1 hour with shaking. Depending on the size of the 
DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD
29 
 
plasmid, 20 – 100 µL of bacterial culture was dropped using a pipette close to the edge of the 
LB agar plate containing 50 µg/mL spectinomycin. An inoculation loop was used to streak the 
dropped bacteria culture on the LB agar plate in a clockwise manner. The plate was incubated 
overnight at 37⁰ C.  
3.4.10.6 Purification of plasmid DNA (miniprep) 
QuickLyse Miniprep Kit (Qiagen, 27505) was used by following the protocols of the 
manufacturer. It was ensured that the OD600 of E. coli cells from 2 mL culture fell between 1.8 
– 2.2 using a nano-spectrophotometer (Denovix). If it is greater than 2.2, the culture was 
diluted to 2.0 with deionized DNA-free water. 1.5 mL of the bacteria culture was pipetted into 
2 mL QuickLyse Lysis Tube and centrifuged at 18000 x g for 1 minute at room temperature. 
The supernatant was decanted by inverting the tube on a paper towel. 400 µL of ice-cold 
Complete Lysis Solution (placed on ice) was added to bacteria pellet and vortexed at the 
highest setting for 30 seconds. The vortexing was continued until cell clumps were completely 
resuspended. The lysate was incubated at room temperature for 3 minutes and pipetted into 
a QuickLyse spin column.  The spin column was centrifuged at 17000 x g for 60 seconds. The 
flow-through was decanted and spin column placed back into tube. The spin column was 
washed by adding 400 µL of Buffer QLW and centrifuged at 17000 x g for 60 seconds. The 
flow-through was discarded. The spin column was placed in a new waste tube and centrifuged 
at 17000 x g for 1 minute to dry the spin column. After transferring the spin column into a new 
1.5 mL microcentrifuge tube, 50 µL Buffer QLE was pipetted into the center of the spin column 
to elute DNA by centrifuging at 17000 x g for 60 seconds.  
2.4.10.7 Restriction endonuclease digest 
Restriction enzyme digest carried out was adapted from protocol recommended by New 
England BioLabs (NEB). The purpose of the experiment was to confirm the quality (clean 
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bands and right sizes) of the plasmid purified using the miniprep (Qiagen). Total reaction 
volume was 50 µL for digestion of 1 µg of substrate. In order to identify the right enzyme for 
digestion, the plasmid vector map was viewed on Snapgene software. After identifying at least 
two enzymes, 10U of each enzyme was used for digestion without exceeding 10% of total 
reaction volume (50 µL). Typically, after determining the right volume to be used for each 
reagent, HyPure deionized water (GE Healthcare) was first added into a PCR tube to make 
up the remaining difference of the 50 µL of total reaction volume. Next, 5 µL of Cutsmart buffer 
(NEB) was added into the PCR tube. The type of buffer used depended on the enzyme used. 
The enzymes are better suited to different buffers. This was followed by the addition of 1 µg 
of the plasmid DNA and the right volume of enzymes were added lastly. The PCR tube 
containing reaction volume was incubated in Veriti 96-well thermal cycler (Applied 
Biosystems) at 37⁰ C for 1 hour. While the reaction was incubating, 1% agarose gel was 
poured into an electrophoresis chamber which was allowed to solidify for about 20 - 30 
minutes. 1X TAE buffer was poured into the electrophoresis chamber containing agarose gel 
to a point a little above the gel level. After the samples have finished incubating, 10 µL of 6X 
gel loading dye (New England BioLabs, B7024S) was added to all the samples. 15 µL of each 
sample were loaded into each lane and 10 µL DNA ladder (ThermoFisher, SM0312) in one 
lane. The gel was ran for about 45 minutes – 1 hour at 100V. At the end, the gel was imaged 
(Azure Biosystems, c200) and compared to the predicted image as depicted by the Snapgene 
software gel electrophoresis predictive tool when simulated with the restriction enzymes used.  
3.4.10.8 BigDye® Polymerase Chain Reaction (PCR) cycle sequencing 
Purified DNA plasmid was amplified using BigDye® cycle sequencing (Applied Biosystems) 
protocol as recommended by the manufacturer. The table below shows the amount of reagent 
added for each reaction in a microcentrifuge tube.  
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Table 5: BigDye reaction mix preparation 
 Reagent Quantity 
1. BigDye ready reaction mix 8 µL 
2. Plasmid DNA template (500 – 1000 ng) 2 µL 
3. Primer @ 3.2 pmol/ µL (Forward & Reverse)  1 µL 
4. Deionized water 9 µL 
 Total volume 20 µL 
Each reaction was carried out separately for the forward and reverse primer of the DNA 
template. After adding all reagents in the order listed in Table 3, each tube was mixed well 
and spun briefly. The tubes were placed in Veriti thermal cycler (Applied Biosystems), volume 
of reaction set to 20 µL and PCR cycle parameters entered as seen in Table 4 below and 
PCR reaction started.  
Table 6: BigDye PCR reaction parameters 
96⁰ C 1 min  1 cycle 
96⁰ C 10 sec  
50⁰ C (depending on template primer)  5 sec  
60⁰ C 4 min 25 cycles 
4⁰ C ∞ hold 
 
3.4.10.9 DNA sequencing clean-up  
This process was carried out using ZR DNA sequencing clean-up kit (Zymo Research, D4050) 
according to the protocol of the manufacturer. 240 µL of sequencing binding buffer was added 
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to the 20 µL PCR sequencing reaction sample and mixed. The mixture was transferred into 
Zymo-Spin IB Column in a collection tube. The spin column with collection tube was 
centrifuged at 10000 rpm for 1 minute. 300 µL of wash buffer was added to the column and 
centrifuged at 10000 rpm for 1 minute. Spin column was placed into a new 1.5 mL 
microcentrifuge tube. 20 µL of Hi-Di formamide solution was added into the column and 
centrifuged at 10000 rpm for 1 minute. The eluted PCR product was transferred to a clean 
Axygen 96-well sequencing plate for subsequent use with the sequencing instrument.  
3.5 PROTEIN ANALYSIS 
3.5.1 Bicinchoninic acid (BCA) Protein Assay (microplate procedure) 
A stock of the diluted standards (Bovine serum albumin-BSA) was prepared in clean 
Eppendorf tubes with concentration ranging from 2000 µg/mL to 25 µg/mL and using the 
diluent (distilled water) as blank. The cell lysate to be tested was diluted to bring total protein 
concentration to between 2000 ug/mL and 25 ug/mL based on historical or previous 
experience with cell type and cell culture condition. 10 uL of each standard and sample in 
duplicates were added to the corner of the well in a clear 96-well plate (Corning, 3641). Finally, 
200 uL of the working reagent (WR) was added into all wells and mixed well by up and down 
pipetting. The microplate was transferred to a Jitterbug (Boekel Scientific, 130000-115V), a 
heated microplate shaker, mixed for 10 minutes and incubated at 37⁰ C for 30 minutes. 
Thereafter, absorbance reading was measured at 562nm on a SoftMax plate reader.  
3.5.2 Western Blot (Immunoblotting) 
The harvested cells were pelleted by centrifugation (Eppendorf, centrifuge 5424) at 2500 rcf 
for 10 minutes and supernatant discarded. MPER Mammalian Protein Extraction Reagent Kit 
(Thermofisher, 78501) and Halt Protease Inhibitor cocktail (Thermo Scientific, 87785) were 
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mixed at a ratio of 100:1 respectively. A certain amount of volume (depending on the cell 
density) of the mixture, between 100 – 400 uL was added to the pelleted cells. This was mixed 
by pipetting up and down. The mixture was shaken gently for about 10 minutes and 
centrifuged at 14000 rcf for 15 minutes to remove cell debris. Supernatants were transferred 
into a new 1.5 mL microcentrifuge tube (Eppendorf) for storage at 80⁰ C or used immediately 
for sample preparation. The samples were prepared with a mix of sample buffer, reducing 
agent and distilled water using manufacturer protocol. The samples were then heated to 95⁰ C 
in a microcentrifuge heating block (VWR) for 10 minutes. Samples were loaded into wells in 
a 4 - 12% SDS-polyacrylamide gel Nupage premade gels (Novex, Invitrogen by Thermo 
Scientific) containing 1X MOPS SDS running buffer (Novel by Life Technologies, NP0001). 
10 uL of SeeBluePlus2 pre-stained protein ladder (Thermo Scientific, LC5925) was used as 
a molecular weight standard. Required volume of samples depending on gel size used was 
added to the remaining wells. Gel was ran in a PowerPac 200/300 electrophoresis power 
supply (Biorad) at 100V for 5-10 minutes, then increased to 110V after samples were out of 
the wells and into the stacking gel. Samples were allowed to run until they get to the bottom 
of the gel. The stacked gel casing was rinsed with deionized water. Proteins were transferred 
from the gel to a nitrocellulose membrane using the iBlot 2 dry blotting system (Life 
Technologies) with iBlot 2 transfer stacks (Invitrogen, IB23002). The membranes were 
allowed to wash in a blocking buffer (Thermo Scientific, 37543) for 1 hour on a shaker at room 
temperature. The following primary antibodies: human SUMF1 (1:1000 #TA337720 Origene), 
mouse/human SUMF1 (1:500 #MAB2779 R&D Systems), GAPDH (1:5000 #PA1-988 Thermo 
Scientific), were diluted in blocking buffer and used to probe the membrane overnight at 4⁰ C 
on a shaker. Next, the membranes were probed with fluorochrome-conjugated secondary 
antibodies and detected with Odyssey CLx Imaging System (LICOR Biosciences) after 1 hour 
of incubation.  
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ABSTRACT 
Chinese hamster ovary (CHO) cells have become the workhorse for the manufacturing of 
recombinant therapeutic protein and the use of a fed-batch biphasic (temperature shift at 
the early part of cell growth) process have tremendously improved the volumetric yield of 
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most well understood therapeutic proteins. However, difficult-to-express (DTE) recombinant 
therapeutic protein like complex multi-specific proteins, DTE mAbs, and lysosomal enzymes 
have seen difficulties in manufacturability of CHO cells and other mammalian cells as 
production platforms. In addition, genetic heterogeneity and clonal variations in CHO cell 
lines have been shown to produce cells with variable cellular growth rate, product yield and 
specific productivity. In this study, we sought to understand the gene and miRNA expression 
profile dynamics of three in-house CHO cell lines (non-producer, low and high producers) 
stably secreting a DTE lysosomal protein but differ in their growth rate, specific productivity 
and titer. MicroRNA are short non-coding RNA with 18-24 nucleotide in length. They have 
been shown to play major roles in various cellular processes with relevance and impact in 
bioprocessing phenotypes. Next-generation sequencing (NGS) technology was employed 
for mRNA and miRNA expression analysis of samples taken on day 3, 5, 7 and 10 from 
CHO cells grown in a 5L fed-batch biphasic bioreactor. The RNA-Seq and small RNA-Seq 
data were analyzed by the Bioinformatics group at BioMarin. Correlation and differential 
analyses from the analyzed data identified 500 mRNAs and 35 miRNAs that were 
differentially expressed (DE) in the in-house CHO cell lines over cultivation period. 
Meanwhile, from the 35 DE miRNAs, cgr-miR-31-5p represent the top DE miRNA with an 
upregulation of 131 fold in the higher producer compared to the lower producer. In addition, 
correlation results of mRNA and miRNA expression profile were also determined. Taken 
together, this study has been able to provide miRNA and mRNA expression dynamic 
changes in CHO clones that differ in growth and productivity profiles, while providing 
potential targets for CHO cell engineering for desirable bioprocess phenotype. 
 
Keywords: Chinese hamster ovary (CHO cells), cell engineering, microRNA (miRNA), 
lysosomal protein, Next generation sequencing (NGS), difficult-to-express (DTE) 
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Among mammalian cells used for recombinant therapeutic production, CHO cell has 
remained the dominant player as most approved biologics were manufactured in CHO cells. 
Moreover, tremendous efforts by scientists have helped in pushing the productive capacity 
of CHO cells to a much higher volumetric yield via media optimization (Buchsteiner et al. 
2018; Clincke et al. 2011), cellular (Dorai et al. 2010; Druz et al. 2013), process (Gagnon et 
al. 2011) and genetic engineering (Rajendra, Peery, and Barnard 2016; Jazayeri et al. 
2018). However, the latter approach entails the manipulation of gene expression which 
could add an extra translational burden on the host cell (Migani, Smales, and Bracewell, 
2017). Recently, microRNA-engineering of CHO cells have shown proven efficacy at 
improving cell specific productivity (Fischer, Paul, et al. 2015; Kelly et al. 2015; Meyer et al. 
2017; Emmerling et al. 2016; Loh et al. 2014), growth rate (Strotbek et al. 2013), and 
apoptosis resistance (Druz et al. 2013) in CHO cell lines expressing less complex and well 
understood recombinant therapeutic proteins.  
MicroRNA (miRNA) are small (18-24 nucleotide) non-coding RNA with the ability to regulate 
~30% of gene expression in cells post-transcriptionally (Pasquinelli 2012; Bratkovič et al. 
2012; Winter et al. 2009; Ha and Kim 2014). The pleiotropic function of most miRNA allows 
one miRNA to target more than one mRNA transcripts (Fischer, Handrick, et al. 2015). 
MiRNA transcription begins at the nucleus and is transcribed by RNA polymerase II into a 
long primary transcript (pri-miRNA) with multiple stem loops. Thereafter, the pri-miRNA is 
processed in the nucleus by microprocessors (Drosha and DGCR8) into a hairpin structure 
(~72 nt long) called precursor miRNA (pre-miRNA) and exported via exportin-5 (XPO5) into 
the cytoplasm in a RanGTP-dependent manner.  While in the cytoplasm, Dicer, an 
endoribonuclease, trims the stem loop of the pre-miRNA forming a miRNA duplex (~22 nt) 
which consist of 5p or 3p mature strands. Either the 5p or 3p strand is selected (the other is 
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either degraded, but not in all cases) for attachment with Argonaute protein family to form a 
complex called miRNA-induced silencing complex (miRISC). The miRNA directs the 
miRISC to a potential mRNA transcript target for inactivation via translational repression, 
deadenylation or degradation (O’Brien et al. 2018; Pasquinelli 2012). A couple of studies 
have used next generation sequencing (NGS) (Hackl et al. 2011; Stiefel et al. 2016; Monger 
et al. 2015; Hammond et al. 2012), microarray technology (Maccani et al. 2014; Klanert et 
al. 2016; Bort et al. 2012; Harreither et al. 2015), mass spectrometry (Clarke et al. 2012; 
Meleady et al. 2011) and microRNA library (Strotbek et al. 2013) to profile the transcriptome 
(miRNA and/or mRNA) or proteome in CHO cells cultivated either in batch (Clarke et al. 
2012; Bort et al. 2012; Harreither et al. 2015), fed-batch (Stiefel et al. 2016; Klanert et al. 
2016; Meleady et al. 2011), steady-state mode (Maccani et al. 2014) or in adherent cell 
culture (Hammond et al. 2012; Hackl et al. 2011). However, only few of these studies have 
used CHO cell lines secreting a difficult-to-express (DTE) protein. Studies that have 
evaluated mRNA and/or miRNA expression profile changes in CHO cells secreting DTE 
protein (e.g. EPO-Fc fusion protein) either used microarray technology for analysis or 
steady-state cultivation of the CHO cell lines (Maccani et al. 2014; Klanert et al. 2016); 
microarray technology doesn’t have the high sensitivity of NGS for low (or rare) and high 
gene abundance (Hurd and Nelson 2009) just as steady-state cultivation may not give a 
true picture of miRNA expression changes as in a traditional fed-batch process commonly 
used in the industry. Currently, few works have be done testing the limit of miRNA-
engineering of CHO cells secreting DTE proteins such as complex multi-specific proteins, 
DTE mAbs. However, most DTE proteins like lysosomal enzymes have seen difficulties in 
manufacturability using CHO cells or other mammalian cells as production platforms 
(Migani, Smales, and Bracewell 2017; Liu et al. 2017).  
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In this study, we sought to understand transcriptional (mRNA and miRNA) expression 
changes in CHO cell lines (CHO-lys-low producer, CHO-lys-high producer, and CHO-non-
producer) secreting a DTE lysosomal enzyme and cultivated in a fed-batch biphasic mode 
within a 5L bioreactor.  500 DE mRNA (FDR<0.05 & FC>2 or <0.5) and 35 DE miRNA 
(FDR<0.05) were identified. Among the 35 DE miRNAs, cgr-miR-31-5p was found to be 131 
fold upregulated in CHO-lys-high producer compared to CHO-lys-low producer. In addition, 
miRNA associated with growth rate and titer were also determined.  
4.1 Materials and Methods 
4.1.1 Cell lines and cell culture 
CHO suspension cell line (CHO-non-producer) and two other in house producer cell lines 
derived as clones from the CHO-non-producer stably express a lysosomal protein and were 
cultivated in CD CHO medium (Thermo Scientific, Waltham, MA, USA), but supplemented 
with 8 mM GlutaMax (Thermo Scientific, Waltham, MA, USA) for CHO-non-producer only. 
The producer cell lines differ by their specific productivity (also in titer and growth rate), so 
are identified as low and higher producer relative to their production capacity. The high 
producer (CHO-lys-high) have a specific productivity and titer that is 3x and 2x higher 
respectively compared to the low producer (CHO-lys-low). However, CHO-lys-low shows a 
growth rate that is 2x that of the CHO-lys-high producer. Inoculation cells were sourced from 
cells maintained with a working volume of 30-150 mL within a shake flask (Corning, 
Oneonta, NY, USA) at 37⁰C, 5% CO2 and 80% humidity in an orbital shaker incubator 
(Infors HT, Annapolis Junction, Maryland, USA) agitated at 125 rpm. Cells were passaged 
every 3-4 days at a seeding density of 0.5 x 106 cells/mL. Cell concentration and viability 
were measured using the ViCellTM (Beckman Coulter, Brea, CA, USA) by the trypan blue 
exclusion method. For functional validation study of target miRNAs, CHO suspension cells 
DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD
40 
 
were cultivated in CD CHO medium ((Thermo Scientific, Waltham, MA, USA) at a seeding 
density of 0.9-1 x 106 cells/mL and propagated in a 6-well plate for 72 hours (Life 
Technologies, Grand Island, New York). Culture was maintained at 37⁰ C, 5% CO2 and 
80% humidity in a static incubator (Thermo Scientific, Waltham, MA, USA) and samples 
taken at 48 h and 72 h for RNA isolation and protein concentration/western blotting analysis 
respectively.  
 
4.1.2 Bioreactor fed-batch cultivation 
CHO-non-producer, CHO-lys-low, and CHO-lys-high producer cell lines were cultivated in 
5L Dasgip bioreactors in a biphasic (temperature shift on D5, from 37⁰C to 30⁰C) fed-batch 
mode. The bioreactors were inoculated at a seeding density of ~0.4 x 106 cells/mL with a 
working volume of 3L and cultivated for 14 days. The cells were cultured in a CD CHO 
medium (Thermo Scientific, Waltham, MA, USA) and maintained at 37⁰C, pH 6.9 (Figure 
3D), dissolved oxygen 30% and 80 rpm agitation. On day 3 and 5, 5% and 10% efficient 
feed B media was added respectively. In addition, to maintain adequate supply of energy 
source for cells to growth and synthesize products, glucose levels were maintained at 2 g/L. 
Moreover, offline monitoring of cell health, substrate, and metabolic concentrations were 
measured using the ViCellTM (Beckman Coulter, Brea, CA, USA) by the trypan blue 
exclusion method for cell concentration and viability, while the Bioprofile Flex Analyzer 
(Nova Biomedical, Waltham, MA, USA) was used for glucose, lactate, glutamine, and 
glutamate concentration measurements.  
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4.1.3 Transient transfection of mimics and inhibitors 
Transient transfection of miRNA mimics (mmu-miR-31-5p) and inhibitors (anti-mmu-miR-
31-5p) (Qiagen, Germantown, MD, USA; Dharmacon, GE Healthcare, Lafayette, CO, USA) 
were carried out using LipofectamineTM RNAiMax (Thermo Scientific, Waltham, MA, USA) 
transfection reagent and Opti-MEM I (Thermo Scientific, Waltham, MA, USA) reduced 
serum medium for complex formation at a final concentration of 50 nM, unless indicated 
differently. The scramble universal negative control (Sigma-Aldrich, Louis, MO, USA) was 
used as a non-targeting control (NT-siRNA).  
 
4.1.4 Real-time Quantitative Reverse-Transcription PCR (qRT-PCR) 
Briefly, cDNA was synthesized from 1 μg of total RNA using miScript II kit (Qiagen, 
Germantown, MD, USA) for quantification of mature miRNA(s) expression and Superscript 
Vilo kit (Invitrogen, Thermo Scientific, Carlsbad, CA, USA) for gene expression 
quantification according to the protocol of the manufacturers. For the quantification of 
matured miRNAs and gene expression, qRT-PCR was performed with 10-1 diluted cDNA on 
a LightCycler 480 (Roche Molecular Diagnostics, Pleasanton, CA, USA) using SsofastTM 
Evagreen® Supermix (BioRad, Hercules, CA, USA) according to the protocols of the 
manufacturer. GAPDH and U6 snoRNA were used for the normalization of gene expression 
and mature miRNA expression levels respectively. miScript Universal Reverse Primer 
(Qiagen, Germantown, MD, USA) was used for mature miRNA analysis. Details of primers 
used for qRT-PCR (Table 14). For the quantification of relative gene expression, the 
comparative C (T) method was employed. 
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4.1.5 Western blot analysis 
Protein extraction on harvested cells was done using the M-PER mammalian Protein 
Extraction Reagent Kit (Thermo Scientific, Carlsbad, CA, USA) according to the protocol of 
the manufacturer. Halt Protease Inhibitor Cocktail (Thermo Scientific, Carlsbad, CA, USA) 
was mixed with the extraction solution at a ratio of 1:100 respectively. Total protein was 
determined using the bicinchoninic acid (BCA) protein assay (Thermo Scientific, Carlsbad, 
CA, USA) according to the protocol of the manufacturer. Cellular proteins were separated 
in a 4-12% SDS-polyacrylamide Nupage premade gels (Thermo Scientific) using a 1X 
MOPS SDS running buffer. Proteins were transferred from the gel to a nitrocellulose 
membrane using the iBlot 2 dry blotting system (Life Technologies). The membranes were 
allowed to wash in a blocking buffer (Thermo Scientific) for 1 hour on a shaker at room 
temperature. The primary antibody against the secreted lysosomal protein was in house and 
sourced in bulk from a biotech company. The other primary antibody used was GAPDH 
(1:5000, PA1-988, Thermo Scientific). All primary antibodies were diluted in blocking buffer 
and used to probe membrane overnight at 4⁰ C on a shaker. Thereafter, the membranes 
were probed with fluorochrome-conjugated secondary antibodies (LICOR Biosciences, 
Lincoln, Nebraska, USA) and detected with Odyssey CLx Imaging System (LICOR 
Biosciences, Lincoln, Nebraska, USA) after 1 hour of incubation. 
 
4.1.6 Enzymatic assay (titer) 
For determination of titer values from sample supernatants, 4-MUGAL was used as 
substrate and carried out in a 96-well plate format. All standard and in-house control 
samples were diluted to appropriate concentrations. Substrate mixture were loaded into 
plate wells, and incubated at 37⁰C for 40 minutes. Fluorescence was read at 325 nm 
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(excitation) and 420 nm (emission) on a SpectraMax M3 plate reader (Molecular Devices, 
San Jose, CA, USA) 
 
4.1.7 Bioinformatics analyses 
To determine the differential expression of global gene and miRNA expression profiles in 
the lower producer (CHO-lys-low), higher producer (CHO-lys-high) and parental cell line 
(CHO-non-producer) and their correlation with relevant bioprocess phenotypes (e.g. growth, 
titer) samples were taken on day 3, 5, 7, and 10 and processed using next generation 
sequencing (NGS) by an external company. The RNA-seq and small RNA-seq data 
analyses was performed by the Bioinformatics group at BioMarin. For NGS, the parameters 
used can be found in Table 7.  The prospective target genes (integration of predicted and 
gene target from RNA-seq data) of the 35 DE miRNAs were obtained from the results of the 
RNA-seq data analyses. Functional annotation of predicted genes was analyzed using 
Database for Annotation, Visualization and Integrated Discovery (DAVID) online tool 
(https://david.ncifcrf.gov/).    
4.2 Results 
4.2.1 Fed-batch cell culture cultivation  
Three CHO cell lines were cultivated in a biphasic fed-batch process using 5L Dasgip 
bioreactors in quadruplicate for each cell line. One of the cell lines is CHO-parental (CHO-
non-producer) and the other two are CHO-lys-low and CHO-lys-high producers derived as 
clones from the parental cell secreting a difficult-to-express (DTE) lysosomal enzyme. CHO-
lys-low and CHO-lys-high producer clones were classified as low and high producers 
respectively based on their relative differences in volumetric and specific productivity (Table 
8). Although, CHO-lys-low has a better growth rate than CHO-lys-high (Figure 2A). To 
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maintain adequate energy source for the growth of the cells, glucose levels was maintained 
at 2 g/L (Figure 3C) after temperature shift to 30⁰C on day 5.  As the common process in 
bioprocessing, the bioreactor temperature reduction to 30⁰C induced a reduction in cell 
growth from day 6 (Figure 2A-B) but an increase in overall cell specific productivity (qP) 
and higher viability maintenance (Figure 2C).  CHO-lys-high showed a qP that is about 
three times 3-fold (1.47-2.88 pg/cell/day) higher than that of CHO-lys-low producer (0.54-
1.01 pg/cell/day) (Figure 3A). In addition, CHO-lys-high showed a titer that is about 2 fold 
(~262 mg/mL) higher than that of CHO-lys-low producer expressing a final mean titer of 
~154 mg/mL after day 14 harvest (Figure 3B). Based on the productivity differences 
between the two clones we sought to understand the gene and microRNA profiles changes 
between these clones, including the parental cell line.  
 
4.2.2 Identification of growth-correlating miRNAs and mRNAs  
To link the expression profile of genes and miRNAs to relevant bioprocess phenotype like 
growth rate and titer, correlation analyses were done by the Bioinfomatics group at 
BioMarin. The LogFC and FDR<0.05 of the miRNAs and mRNAs were applied for 
correlation with growth rate. In total, the number of DE genes that were correlated with 
growth rate in CHO-non-producer, CHO-lys-low producer and CHO-lys-high producer were 
6964, 8637, and 8945 respectively. Furthermore, by overlapping all three cell lines for 
identification of growth-associated genes, 529 positively correlated and 758 negatively 
correlated genes were uniquely identified in the CHO-lys-high producer cell line. For 
miRNAs associated with growth rate in the CHO-non-producer, CHO-lys-low producer and 
CHO-lys-high producer, 62, 81 and 37 miRNAs were identified. By overlapping these three 
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cell lines, 8 miRNAs (2 positively correlated and 6 negatively correlated) (Table 9) 
associated with growth were uniquely identified in CHO-lys-high producer.  
 
4.2.3 Identification of titer-correlating miRNAs and mRNAs 
Likewise, as described above, miRNAs and mRNAs with association to titer in both CHO-
lys-low and CHO-lys-high producers were determined. Overall, 8062 DE genes in CHO-lys-
low and 8093 DE genes in CHO-lys-high were determined to be associated with titer. In 
addition, 1021 positively correlated and 668 negatively correlated genes were uniquely 
identified in the CHO-lys-high producer cell line. Moreover, 88 and 56 miRNAs were 
identified to be associated with titer in CHO-lys-low and CHO-lys-high producer cell lines 
respectively. Overlapping the CHO-lys-low and CHO-lys-high producers, 17 positive 
correlated miRNAs and 5 negative correlated miRNAs were identified to be uniquely 
associated with CHO-lys-high producer (Table 10). Validated targets of these 17 positively 
correlated miRNAs could be seen in Table 15. 
4.2.4 Functional confirmation of miRNA expression by qRT-PCR 
To confirm NGS results, we conducted qRT-PCR on selected 14 DE (FDR<0.05 & FC>2 or 
<0.5) miRNAs derived from the 35 DE (FDR<0.05) miRNAs when CHO-lys-low producer 
was compared to CHO-lys-high producer cell line. The RNA samples tested were taken from 
day 7 after temperature shift on day 5 for each replicate bioreactors and we confirmed that 
the expression of the miRNAs selected across the different cell lines do not overlap on this 
day. Surprisingly, we could only confirm a 15-fold (131 fold From NGS result) increase of 
cgr-miR-31-5p expression in CHO-lys-high producer compared to CHO-lys-low (Figure 4A-
J). Though we observed a 2.43 fold increase in cgr-miR-221-5p expression in CHO-lys-high 
using qRT-PCR, the result was in contrast to the one fold decrease observed from the NGS 
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result. In general, we could confirm the upregulation cgr-miR-31-5p expression in CHO-lys-
high producer compared to CHO-lys-low producer.  
 
4.2.5 Functional effect of miR-31-5p on the secreted lysosomal protein of CHO-lys-  
 low and CHO-lys-high producers 
Since we observed a 15 fold (qRT-PCR) increase in cgr-miR-31-5p expression in CHO-lys-
high producer compared to CHO-lys-low producer, we transiently transfected both cell lines 
with mmu-miR-31-5p mimics and inhibitors and cultured for 72 h in a static condition. In 
addition, miR-31-5p overexpression and downregulation were confirmed after 48 h (Figure 
5A-B). After 72 h of post-transfection using the mimics and inhibitors, we observed no 
significant changes in cell viability and growth profile in the transfected cells compared to 
the non-targeting control (si-NTC) (Figure 6A-B). Surprisingly, overexpression of mmu-miR-
31-5p in CHO-lys-high producer significantly increased the titer of the secreted lysosomal 
protein compared to the scramble (non-targeting control) while downregulation of mmu-miR-
31-5p had no significant effect (Figure 6E). In contrast, overexpression of mmu-miR-31-5p 
decreased the titer of the secreted lysosomal protein of the CHO-lys-low producer (Figure 
6D) and an opposite effect was observed when mmu-miR-31-5p expression was 
downregulated. (Figure 6C).  
4.2.6 Identification of miR-31-5p target genes and functional annotation 
To identify the target genes of miR-31-5p, we used DAVID in silico tool for gene ontology 
(GO) functional cluster analysis. This help identify pathways that are associated with a gene 
or group of genes. This analysis was conducted by using the list of miR-31-5p target genes 
(integration of predicted (by atleast 3 miRNA predictive tool) and NGS DE gene lists). 
Moreover, a mouse gene over a mouse genome function in the DAVID tool was used for 
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the analyses since using a CHO genome background wasn’t comprehensive enough for the 
number of genes tested. Only the annotated clustered groups (~#12) with adj.P.Val<0.2 
(Benjamini or FDR) were selected for downstream analysis (Figure 7A). Genes related to 
protein binding, endoplasmic reticulum, cytoplasm and membrane were highly expressed. 
However, we went ahead to streamline the target genes into 9 potential targets by selecting 
genes with relevant effect on bioprocess phenotypes and those identified in any of the 12 
clustered groups by at least twice. These target genes could be tested for possible functional 
studies to examine the effect of miR-31-5p on the target genes and protein expressions 
(Table 11 & 12).  Furthermore, the expression of the selected genes have been shown in 
different studies to have an effect on protein production, protein trafficking, and cell 
proliferation (Table 13). 
 
4.3 Discussion 
Different studies have evaluated the impact of miRNA and/or mRNA expression profile 
dynamics on relevant bioprocess phenotypes of CHO cells (Harreither et al 2015; Monger 
et al. 2015; Clarke et al. 2012; Bort et al. 2012; Klanert et al. 2016; Stiefel et al. 2016; 
Maccani et al. 2014). Moreover, technologies like next-generation sequencing (NGS), 
microarray and mass spectrometry have been used singly or in combination for standalone 
or integrated analysis of mRNA, miRNA or protein profiles of CHO cells secreting proteins 
such as mAb, SEAP, Epo-Fc. Moreover, much of these studies have indicated that global 
miRNA expression profiles is either product and/or clone specific (Stiefel et al. 2016; 
Maccani et al. 2014). In addition, CHO cell lines expressing well understood recombinant 
protein were mostly used, which might not be indicative when comparing miRNA profile 
dynamics in CHO cell lines secreting difficult-to-express (DTE) lysosomal enzymes. Studies 
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that have evaluated miRNA global expression changes in CHO cells secreting DTE protein 
(e.g. EPO-Fc fusion protein) either used microarray technology for analysis or steady-state 
cultivation of the CHO cell lines (Maccani et al. 2014; Klanert et al. 2016); microarray 
technology doesn’t have the high sensitivity of NGS for low (or rare) and high gene 
abundance (Hurd and Nelson 2009) just as steady-state cultivation may not give a true 
picture of miRNA expression changes as in a traditional fed-batch process. In this study, we 
sought to understand miRNA/mRNA expression changes in CHO cell lines (CHO-lys-low 
producer, CHO-lys-high producer, CHO-non-producer) secreting a DTE lysosomal protein. 
Furthermore, CHO-lys-low producer exhibited a 2 fold increase in growth rate compare to 
CHO-lys-high producer from the lag phase up to the exponential phase during cell culture 
cultivation (Figure 2A). In the production of therapeutic protein this phenomenon holds true 
because the increase in protein synthesis has been seen to be inversely proportional to cell 
growth (Loh et al. 2014). The lower growth rate of CHO-lys-high producer may be 
compensated with a higher productivity since most of the cells machineries are geared 
towards protein synthesis (Lee et al. 1998). The productivity difference between the low and 
high producer clones may be due to differences in their mRNA transcript levels, miRNA 
expression differences or differences in the site of integration of the transgene. We 
conducted a qRT-PCR experiment to ascertain the mRNA levels of the lysosomal protein 
secreted by these cell lines and found that there was no significant differences between the 
two clones at the transcript level (Figure 7B). In addition, clonal variation or CHO cell 
genetic heterogeneity could also a play a role in the differences between the productivity 
yields of these clones (Scarcelli et al. 2018; Derouazi et al. 2006). In order to develop a 
meaningful and reproducible results, these cell lines were grown in a 5L Dasgip bioreactor 
and cultivated for 14 days under a fed-batch biphasic (temperature shift on day 5) condition 
and samples were taken on day 3, 5, 7 and 10 for RNA-seq and small RNA-seq (miRNA) 
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processing. To understand the global mRNA and miRNA profile differences between CHO-
lys-low and CHO-lys-high producers, we identified 500 DE mRNA (FDR<0.05 & FC>2 or 
<0.5) and 35 DE miRNA (FDR<0.05).  
Among the 35 DE miRNAs, cgr-miR-31-5p was found to be 131 fold upregulated in CHO-
lys-high producer compared to CHO-lys-low producer by taking the mean fold change at 
four different time points (day 3, 5, 7, & 10) during cultivation. The high expression profile of 
miR-31-5p in CHO-lys-high producer could explain its high pro-productive nature and/or 
high volumetric yield relative to the CHO-lys-low producer. Joon-Ho Cho et al. were able to 
show that the upregulation of miR-31 by histone deacetylase inhibitor (HDACi) caused an 
induction of cellular senescence in cancer cells (Cho, Dimri, and Dimri 2015). This could 
explain the 2 fold difference in growth rate between CHO-lys-high and CHO-lys-low 
producers. However, from the growth correlating result, miR-31 was positively correlated 
with growth (but not unique to only CHO-lys-high, also found in CHO-non-producer but not 
in CHO-lys-low) and negatively correlated with titer (Table 9 & 10). This could indicate the 
pleiotropic nature of miRNAs expression in different environmental conditions (Fischer, 
Handrick, et al. 2015). 
Looking at the DE miRNAs associated with growth (data not shown), we observed that there 
were more DE miRNAs in the CHO-non-producer and CHO-lys-producer than in CHO-high 
producer. This observation is in contrast with the result by Maccani et al (2014) in which 
they observed much increase in mature miRNAs expression profiles in producer cell lines 
(Maccani et al. 2014). Interestingly, most of the upregulated miRNAs (e.g. miR-409-3p, let-
7f) have been shown to cause a reduction in cellular proliferation when overexpressed. This 
is could be indicative why CHO-lys-high producer exhibited a growth rate that is 2 fold lesser 
compared to CHO-lys-low. Taken together, we have been able to profile the mRNA and 
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miRNA expression in CHO cell lines that differ in their productivity and in addition identified 
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Table 8: Relevant bioprocess characteristics of CHO cell lines used for cell culture in 5L bioreactor  
 
 
CHO-lys-low CHO-lys-high CHO-non-producer 
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Table 9: Growth correlating DE miRNAs unique to CHO-lys-high producer 
 








Table 10: Titer correlating DE miRNAs unique to CHO-lys-high producer 
 




















Table 11: Gene ontology and Functional annotation of miR-31-5p target genes predicted by at least 
3 in silico tools in combination with DE genes from the RNA-Seq data along with potential genes for 
downstream analyses 
 







Genes  Relevant genes to bioprocess 
Cytoplasm 0.0002 151 
MAPK14, NECAB3, MAP3K2, 
PPP2R5A, SMAD3, UBE2I3, EIF5A2 
Membrane 0.046 145 TMED10, PPP2R5A, EIF5A2 
Cytosol 0.054 48 
MAPK14, MAP3K2, PPP2R2A, 
PPP2R5A 
Endoplasmic reticulum 
memb. 0.065 25 TMED10, NECAB3, EIF5A2 
Protein phosphatase 
type 2A regulator 
activity 0.076 5 PPP2R2A, PPP2R5A 
Actin binding 0.084 16  
Phosphatase activity 0.094 9  
Myosin complex 0.094 6  
Protein phosphatase 
regulator activity 0.1 5 PPP2R2A, PPP2R5A 
ATP binding 0.11 41 MAPK14, MAP3K2, UBE2I3 
Protein binding 0.12 88 
MAPK14, NECAB3, PPP2R5A, 
SMAD3 



















Table 12: Genes selected for downstream analysis from the functional annotation result of miR-31 
target genes derived from prediction by at least 3 in silico tools and DE genes from RNA-Seq data.  



























Table 13: Functions of potential miR-31-5p target genes with relevance to bioprocess phenotypes 
 






























Genes # Times represented gene ID                                              Functions Source
MAPK14 4
augmented expression confer repression of lung cancer growth in vitro and 
in vivo. Negatively regulate cell growth and division. Targeting MAPK7 with 
miR-143 has been shown to enhance protein production
Qi and Elion 
2005; Raman et al. 
2007; Keshet and 
Seger 2010; 
Schoellhorn et al, 
2017
TMED10 3
Involved in vesicular protein trafficking. Mainly functions in the early 
secretory pathway Denzel et al, 2000
NECAB3 4
Promotes activation of hypoxia inducible factor-1 (HIF-1) to use glycolysis 
even at normal oxygen levels, or normoxia. Nakaoka et al, 2016
MAP3K2 3
Regulate processes such as cell proliferation, cell differentiation, and cell 
death in eukaryotes from yeast to humans
Qi and Elion 
2005; Raman et al. 
2007; Keshet and 
Seger 2010
PPP2R2A 3
Augmented expression confer repression of lung cancer growth in vitro and 
in vivo. Negatively regulate cell growth and division Xi Liu et al, 2010
PPP2R5A 6
PP2A phosphatase complex, a key negative regulator of the MAP kinase 
pathway. PP2A is regulated by the kinase mTOR. Both enzymes affect 
phosphorylation status of ribosomal protein S6 Mazur et al, 2014
SMAD3 2
The Smad family proteins are critical components of the TGF-β signaling 
pathways. TGF-β are inhibitory growth factors and regulates transcriptional 
responses Kaji et al, 2001
UBE2F 2
Ubiquitination was initially identified as the main process for protein 
degradation. miR-30 overexpression showed decreased SKp2 & Ube2ji mRNA 
levels which enhanced protein production in CHO cells
Nandi et al, 2006; 
Fischer et al, 2015
EIF5A2 4
suppression of EIF5A2 in HGC27 cells led to significant decreases in cell 
proliferation. EIF5A2 positively regulated cyclin D1 and cyclin D3, which play 
important roles in cell proliferation and cell cycle regulation Meng et al, 2015
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Figure 2: Growth profiles of CHO-lys-low producer, CHO-lys-high producer and CHO-non-producer 
(parental cell line) grown in 5L bioreactors in 3L w/v cell culture for 14 days (A) specific growth rate 
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Figure 3: Productivity profiles and offline Glucose concentration/pH trends of CHO-lys-low 
producer, CHO-lys-high producer and CHO-non-producer (parental cell line) grown in 5L 
bioreactors in 3L w/v cell culture for 14 days (A) Specific productivity (B) Titer (C) Glucose 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4: qRT-PCR confirmation of 14 DE (FDR<0.05 & FC>2 or <0.5) miRNAs selected from 35 
DE (FDR<0.5) miRNAs identified by small RNA-Seq over cell culture duration. MiRNA expression 
was normalized to U6 snoRNA. Error bars represent the standard error of mean (SEM) of three 
independent experiments (n=3). For statistical analysis, one-way ANOVA comparing the mean 
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Figure 5: Quantitative real-time PCR (qRT-PCR) analyses. Cells were transiently transfected with 
5O nM of miR-31-5p mimics or inhibitors in CHO-lys-low producer expressing DTE lysosomal 
enzyme. Cell lysates harvested 48 h post-transfection (A) Endogenous miR-31-5p levels post-
transfection with miR-31-5p inhibitor (B) Endogenous miR-31-5p levels post-transfection of miR-31-






































































































































































































































































































































































Figure 6: Growth profile of CHO-lys-low producer post-transfection with (A) mouse miR-31-5p 
mimic (B) mouse miR-31-5p inhibitor (C) Product concentration (titer) of lysosomal enzyme 
secreted by CHO-lys-low producer post-transfection of mouse miR-31-5p inhibitor (D) Product 
concentration (titer) of lysosomal enzyme secreted by CHO-lys-low producer post-transfection of 
mouse miR-31-5p mimic  (E) Product concentration (titer) of lysosomal enzyme secreted by CHO-
lys-high producer post-transfection of mouse miR-31-5p mimic and inhibitor. Error bars represent 
the standard error of mean (SEM) of three independent experiments (n=3). Error bars represent the 
standard error of mean (SEM) of three independent experiments (n=3). For statistical analysis, 
student t-test was used (* P < 0.05; ** P < 0.01; *** P < 0.001). 
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Figure 7: (A) Functional annotation clustering of DE target genes of miR-31-5p predicted by at 
least 3 in silico tools in combination with miRNA-target gene result from the NGS data analyses. (B) 
Quantitative real-time PCR (qRT-PCR) analyses of day 3 RNA samples used for NGS for both 
CHO-lys-low and CHO-lys-high producer cell lines. mRNA levels of GALC. 
 




Table 14: Primers used for miRNA and mRNA expression analyses using qRT-PCR 
Gene ID Forward primer (5’ – 3’) Reverse Primer (5’ – 3’) 
GAPDH AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC 
U6 snoRNA CTCGCTTCGGCAGCACA AACGCTTCACGAATTTGCGT 
Lysosomal gene  proprietary proprietary 
cgr-miR-31-5p AGGCAAGAUGCUGGCAUAGCUG Qiagen universal reverse 
primer 
 
Table 15: miRTarbase (v 7.0) list of validated targets of positively titer-correlating miRNAs unique 
to CHO-lys-high producer cell line 
miRNA Validated 
targets  
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Inhibitory impact of miR-23a/miR-377 on SUMF1 in CHO 
cells enhances difficult-to-express recombinant 
lysosomal sulfatase activity  
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ABSTRACT 
Difficult-to-express (DTE) recombinant proteins like multi-specific proteins, DTE monoclonal 
antibodies and lysosomal enzymes, have seen difficulties in manufacturability using 
Chinese hamster ovary (CHO) cells and other mammalian cells as production platforms. 
CHO cells are preferably used for protein production because of their innate ability to secrete 
human-like recombinant proteins with post-translational modification, resistance to viral 
infection and familiarity with drug regulators. However, despite huge progress made in 
engineering CHO cells for high volumetric productivity, DTE proteins like recombinant 
lysosomal sulfatase represent one of the poorly understood proteins. Furthermore, there 
are growing interest in the use of microRNA (miRNA) to engineer CHO cells expressing 
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DTE proteins to improve cell performance of relevant bioprocess phenotypes. To our 
knowledge, no research has been done to improve CHO cell production of DTE recombinant 
lysosomal sulfatase using miRNA. We identified miR-23a and miR-377 as miRNAs targeting 
SUMF1 using in silico prediction tools as SUMF1 is an activator of sulfatases. Transient 
inhibition of endogenous miR-23a/miR-377 significantly enhanced recombinant sulfatase 
enzyme specific activity in CHO cell without affecting cell growth. Though, inhibition of miR-
23a/miR-377 had no significant effect on the mRNA and protein levels of SUMF1, 
overexpression of miR-23a/377 significantly reduced both the mRNA and protein levels of 
SUMF1. In summary, our data demonstrates the importance of using miRNA to optimize 
CHO cell line secreting DTE recombinant lysosomal sulfatase.  
 
 
Keywords: Chinese hamster ovary (CHO cells), cell engineering, microRNA, lysosomal 
protein, sulfatase, miR-23a, miR-377 
 
 
Abbreviations: CHO, Chinese hamster ovary; DTE, difficult-to-express; SUMF1, sulfatase 
modifying factor 1; miRNA, microRNA; UTR, untranslated region; FGE, formylglycine 
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5.0    Introduction 
The use of mammalian cells, most especially CHO, as a production platform for recombinant 
therapeutic proteins has increased for decades because of its ability to secrete proteins with 
similar post-translational modifications (PTM) like humans (Fliedl, Grillari, and Grillari-
Voglauer 2015). Though significant improvements have been made at increasing specific 
and volumetric productivities of cells using media optimizations (Clincke et al. 2011; 
Buchsteiner et al. 2018), process improvements (Huang et al. 2010; Gagnon et al. 2011) 
and genetic engineering (Jazayeri et al. 2018), there have been limitations especially for 
difficult-to-express (DTE) proteins with very low production titers or improper folding 
compared to biomanufacturing standards. The production of recombinant therapeutic 
lysosomal proteins have not experienced the tremendous improvements in protein 
production as seen in most monoclonal antibodies, secreted alkaline phosphatase (SEAP), 
and other easy-to-express proteins. Though classical cell engineering of cells has been 
done by the overexpression or knockdown of protein coding genes, this approach introduces 
additional translational burden and cellular limitations.  
In recent years, there has been growing interest in the use of microRNA (miRNA) to 
engineer CHO cells for improvement in cell performance of relevant bioprocess phenotypes 
(Jadhav et al. 2012; Niall Barron 2012; Jadhav et al. 2013; Stiefel et al. 2016). MiRNAs are 
short non-coding RNA molecules, about 18-24 nucleotide long; they negatively regulate 
gene expression post-transcriptionally via translation repression or mRNA degradation 
without adding any translational burden to the cell machinery unlike protein-coding genes. 
In addition, miRNA can regulate an entire network of genes (Galatenko et al. 2018) and it 
regulate gene expression by acting as a rheostat (Baek et al. 2008), partially reducing 
protein expression unlike small-interfering RNAs (si-RNAs) that most often completely 
obliterate their protein target. MiRNA regulate gene expression by binding to the 3’ 
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untranslated region (UTR) of their mRNA target by using their “seed” region located at the 
5’ region of the miRNA. Based on these desirable qualities of miRNA, scientist have 
engineered CHO cells to optimize relevant bioprocess phenotypes e.g., apoptosis (Druz et 
al. 2013), cell proliferation (Hackl et al. 2014), and specific productivity (Strotbek et al. 2013; 
Loh et al. 2014; Meyer et al. 2017; Fischer, Paul, et al. 2015; Loh, Yang, and Lam 2017; 
Inwood et al. 2017; Emmerling et al. 2016). However, most of the CHO cell lines used only 
secreted easy-to-express recombinant proteins and only of recent has miRNA engineering 
of CHO cell line expressing DTE proteins been tested. MiR-143 and miR-557 has been 
shown to enhance protein production and improve cell line development respectively in 
CHO cell lines expressing DTE monoclonal antibodies (Schoellhorn et al. 2017; Fischer et 
al. 2017; Strotbek et al. 2013). MiR-143 exhibited this attribute by repressing mitogen-
activated protein kinase (MAPK7) and MAPK pathways has been shown to regulate gene 
transcription, protein synthesis and differentiation (Kyriakis and Avruch 2001). In addition, 
target gene for miR-557 has not been identified till date. 
Previous study (Frankel et al. 2014) demonstrated that by inhibiting miR-95, which regulates 
the expression of residual sulfatase modifying factor 1 (SUMF1), sulfatase activity could be 
increased. In this study, Frankel et al. transfected human cancer lines and fiboblasts to 
demonstrate the effect of miR-95 which is a non-conserved (not found in mice) miRNA. 
SUMF1 plays a crucial role in the production of lysosomal sulfatase proteins, since it 
encodes Cα-formylglycine (FGly)-generating enzyme (FGE) which activates sulfatases by 
converting their cysteine residue to active FGly. In addition, inhibition of miR-23 has been 
shown to increase CHO cell productivity by increasing oxidative metabolism (Kelly et al. 
2015).  However, the CHO cell secretes an easy-to-express SEAP protein which may be 
unable to stretch the full capability of the miRNA engineering function.  
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In this study, we sought to identify and functionally test miRNA(s) that target SUMF1 and 
improve recombinant sulfatase specific activity. MiR-23a and miR-377 were identified to 
target SUMF1 using in silico computational predictive tools e.g., TargetScan, miRanda-
mirSVR, Diana-microT-CDS, Diana-Tarbase and miRecords. Following this, we used an in-
house CHO cell line stably expressing a recombinant lysosomal sulfatase enzyme for cell 
line engineering. Furthermore, transient functional inhibition of endogenous miR-23a/miR-
377 using miR-23a/miR-377 antimiRs enhanced recombinant sulfatase enzyme specific 
activity in CHO-sulfatase cell without affecting cell growth. Though, inhibition of miR-
23a/miR-377 had no significant effect on the mRNA and protein levels of SUMF1, 
overexpression of miR-23a/miR-377 significantly reduced both the mRNA and protein levels 
of SUMF1.  
5.1  Materials and Methods 
5.1.1 Cell culture 
CHO suspension cells stably expressing sulfatase protein (CHO-sulfatase) were cultivated 
in CD CHO medium (Thermo Scientific, Waltham, MA, USA) and routinely propagated in 6-
well plates (Life Technologies, Grand Island, New York) and maintained at 37⁰C, 5% CO2 
and 80% humidity in a static incubator (Thermo Scientific, Waltham, MA, USA). Inoculation 
cells were sourced from cells maintained in 30-60 mL shake flask (Corning, Oneonta, NY, 
USA) at 37⁰C, 5% CO2 and 80% humidity in an orbital shaker incubator (Infors HT, 
Annapolis Junction, Maryland, USA) with agitation at 125 rpm. Cells were passaged every 
3-4 days at a seeding density of 0.5 x 106 cells/mL. Cell concentration and viability were 
measured using the ViCellTM (Beckman Coulter, Brea, CA, USA) by the trypan blue 
exclusion method. HEK293, HT1080 and MCF7 cells were cultivated in DMEM medium 
supplemented with 10% FBS (VWR, Radnor, PA, USA), and 2 mM GlutaMAXTM (Thermo 
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Scientific, Waltham, MA, USA). The mammalian cells were routinely propagated in T75 
flasks (Corning, Oneonta, NY, USA).  
 
5.1.2 Transfection 
Transient transfection of miRNA mimics, inhibitors and siRNAs (Qiagen, Germantown, MD, 
USA; Dharmacon, GE Healthcare, Lafayette, CO, USA) were carried out using 
LipofectamineTM RNAiMax (Thermo Scientific, Waltham, MA, USA) transfection reagent and 
Opti-MEM I (Thermo Scientific, Waltham, MA, USA) reduced serum medium for complex 
formation at a final concentration of 50 nM, unless indicated differently. Anti-SUMF1 
SMARTpoolTM siRNAs (mouse si-SUMF1) (Dharmacon, GE Healthcare, Lafayette, CO, 
USA), which comprises of a mixture of 4 siRNAs, was used as a functional control and the 
scramble universal negative control (Sigma-Aldrich, Louis, MO, USA) as a non-targeting 
control (NT-siRNA).   
 
5.1.3 RNA Isolation 
Total RNA, including small RNA, was extracted using Quick-RNA Microprep kit (Zymo 
Research, Irvine, CA, USA) according to the protocol of the manufacturer from samples 
harvested from cell culture 48 days post-transfection. The concentration and purity of the 
RNA was determined by UV-spectrometry using a DS-11 spectrophotometer (DeNovix, 
Wilmington, DE, USA) by measuring absorbance at 230, 260, and 280 nm.  
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5.1.4 Real-time Quantitative Reverse-Transcription PCR (qRT-PCR) 
Briefly, cDNA was synthesized from 1 μg or 500 ng (where applicable) of total RNA using 
miScript II kit (Qiagen, Germantown, MD, USA) for quantification of mature miRNA(s) 
expression and Superscript Vilo kit (Invitrogen, Thermo Scientific, Carlsbad, CA, USA) for 
gene expression quantification according to the protocol of the manufacturers. For the 
quantification of matured miRNAs and gene expression, qRT-PCR was carried out with 10-
1 diluted cDNA on a LightCycler 480 (Roche Molecular Diagnostics, Pleasanton, CA, USA) 
using SsofastTM Evagreen® Supermix (BioRad, Hercules, CA, USA) according to the 
protocols of the manufacturer. GAPDH and U6 snoRNA were used for the normalization of 
gene expression and mature miRNA expression levels respectively. miScript Universal 
Reverse Primer (Qiagen, Germantown, MD, USA) was used for mature miRNA analysis. 
Details of primers used for qRT-PCR (supporting information Table S1). For the 
quantification of relative gene expression, the comparative C(T) method was employed. 
 
5.1.5 Western blot analysis 
Protein extraction on harvested cells was done using the M-PER mammalian Protein 
Extraction Reagent Kit (Thermo Scientific, Carlsbad, CA, USA) according to the protocol of 
the manufacturer. Halt Protease Inhibitor Cocktail (Thermo Scientific, Carlsbad, CA, USA) 
was mixed with the extraction solution at a ratio of 1:100 respectively. The total protein of 
the protein extract was determined using the bicinchoninic acid (BCA) protein assay 
(Thermo Scientific, Carlsbad, CA, USA) according to the protocol of the manufacturer. 
Cellular proteins were separated in a 4-12% SDS-polyacrylamide Nupage premade gels 
(Thermo Scientific) using a 1X MOPS SDS running buffer. Proteins were transferred from 
the gel to a nitrocellulose membrane using the iBlot 2 dry blotting system (Life Technologies) 
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according to the protocols of the manufacturer. The membranes were allowed to wash in a 
blocking buffer (Thermo Scientific) for 1 hour on a shaker at room temperature. The following 
primary antibodies: human SUMF1 (1:1000, TA337720, Origene, Rockville, MD, USA), 
mouse/human SUMF1 (1:500, MAB2779, R&D Systems), GAPDH (1:5000, PA1-988, 
Thermo Scientific), were diluted in blocking buffer and used to probe the membrane 
overnight at 4⁰ C on a shaker. Thereafter, the membranes were probed with fluorochrome-
conjugated secondary antibodies (LICOR Biosciences, Lincoln, Nebraska, USA) and 
detected with Odyssey CLx Imaging System (LICOR Biosciences, Lincoln, Nebraska, USA) 
after 1 hour of incubation. 
 
5.1.6 Sulfatase enzymatic activity and Elisa assays  
For determination of enzymatic activity of sulfatase in sample supernatant, 4-
methylumbelliferyl (4-MU) sulfate was used as substrate and incubated in 0.2M NaOAc 
buffer (pH 5.6). 0.4M phosphate buffer (pH 6.7) was used to stop reaction and fluorescence 
was read at 355 nm (excitation) and 460 nm (emission) on a SpectraMax M3 plate reader 
(Molecular Devices, San Jose, CA, USA). Sulfatase protein concentration of sample 
supernatant was determined using an Elisa assay. Sulfatase was captured in a binding 96-
well plate, washed and blocked with a washing and blocking buffer respectively.  Anti-mouse 
HRP antibody was used to bind detection antibody and reaction detected using QuantaBlu 
fluorogenic peroxidase substrate kit (Thermo Scientific, Carlsbad, CA, USA) according to 
the manufacturer’s protocol. Fluorescence was read at 325 nm (excitation) and 420 nm 
(emission) on a SpectraMax M3 plate reader (Molecular Devices, San Jose, CA, USA) 




MiRNAs targeting SUMF1 mRNA were determined using computational prediction tools. 
The following tools were employed: TargetScan (v.7.1), miRanda-mirSVR (Aug’10), Diana-
microT-CDS (v5.0), Diana-Tarbase (v.8) in combination with miRecords (April 27, 2013). 
MiRNAs predicted to target SUMF1 in mouse was used since there are no current target 
prediction tool for CHO cells. Only potential miRNAs predicted to target SUMF1 mRNA by 
at least four prediction tools were considered for downstream functional analysis.  
 
5.2 Results 
5.2.1 In silico identification of putative miRNAs targeting SUMF1 
Frankel et al (2014) showed  that non-conserved miR-95 have an indirect effect on sulfate 
metabolism by regulating SUMF1 gene (Frankel et al. 2014). In addition, they found out that 
by inhibiting miR-95, the enzymatic activity of Arylsulfatase B (ARSB) is increased. To 
improve the specific activity of an in-house CHO cell expressing a sulfatase, we set out to 
identify conserved miRNA(s) targeting SUMF1. Overall, 62 microRNAs (Table 17) were 
predicted altogether by the four bioinformatics tools used and 234 (includes the 62 
microRNAs) by miRecords. Only 6 of the 62 microRNAs predicted by all four prediction tools 
were selected for downstream functional studies. Two of these miRNAs (miR-23a-3p and 
miR-377-3p) predicted to target SUMF1 were pursued further. 
 
5.2.2 Characterization of different mammalian cells to determine appropriate 
  SUMF1 antibody  
In order to determine the appropriate SUMF1 antibody for this study we went ahead to test 
different mammalian cell lines for the expression of endogenous SUMF1 protein. A total of 
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four different mammalian cell types were used: CHO, HT1080, HEK 293, and MCF7. For 
the CHO cell lines, three different cell types were used. One of the CHO cell line clone stably 
expresses a recombinant sulfatase and human SUMF1, the other stably expresses only a 
recombinant sulfatase and the last is a parental CHO cell line expressing no recombinant 
protein. In addition, the three different SUMF1 antibodies were tested on the mammalian 
cell lines in both reduced and non-reduced condition in a Western blot. As expected, the 
human anti-SUMF1 antibody only detected the human recombinant SUMF1 stably 
expressed by one of the CHO cell lines in both reduced and non-reduced conditions (Figure 
8A). In like manner, mouse/human anti-SUMF1 antibody only detected the human 
recombinant SUMF1 stably expressed by one of the CHO cell lines in both reduced and 
non-reduced conditions except the detection of a small SUMF1 band in HEK 293 cells in 
reduced condition. However, mouse anti-SUMF1 antibody detected endogenous SUMF1 in 
all cell line tested except for HEK293 in a reduced condition. However, in non-reduced 
condition, only the HEK293 and MCF7 endogenous SUMF1 were not detected. In addition, 
si-hSUMF1 (siRNA) optimal concentration for transfection was also tested (Figure 14A-B). 
5.2.3 Transient transfection of miR-23a and miR-377 mimics reduced SUMF1 
protein and mRNA levels with no effect on sulfatase activity  
We employed transient transfection to investigate the effect of the two miRNA mimics on 
sulfatase enzyme activity in a CHO cell line stably secreting lysosomal sulfatase. We 
observed that both mimics caused a reduction in SUMF1 protein (Figure 10A) and mRNA 
(Figure 10B) levels. The reduction in SUMF1 protein 48 h post miRNA transfection was 
more pronounced in cells transiently transfected with miR-23a compared to the scramble. 
Surprisingly, the mimics had no significant effect on the sulfatase enzyme titer (Figure 9B) 
and specific activity (Figure 9C). All cells transfected with miRNA mimic had similar cell 
growth profiles compared to the scramble (Figure 9A). Next, we tested the effect of various 
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concentrations of miR-23a mimics using the following concentrations: 10, 25, 50, 100 and 
200 nM. Overall, miR-23a titration concentrations resulted in a decrease in protein (Figure 
13B) and mRNA (Figure 13C) levels of SUMF1 with no effect on growth (Figure 13A). 
However, the reduction in mRNA levels from 10, 50 and 200 nM of miR-23a mimics was not 
significant and including 100 nM of miR-23a mimic at the protein level. Increased levels of 
mature miR-23a-3p and/or miR-377-3p were observed 48 h post-transfection following 
transient overexpression of miR-23a and/or miR-377 respectively (Figure 10C & Figure 
13D). 
5.2.4 Transient inhibition of miR-23a and miR-377 enhances recombinant sulfatase 
enzyme specific activity in CHO cell line 
We sought to investigate the effect of transiently knocking down miR-23a and miR-377 
expression on the specific activity of sulfatase stably secreted in a CHO cell line. To do this, 
mouse and CHO cells antimiRs were used knowing that they exhibited similar mature miR-
23a and miR-377 sequences (Figure 8B). Surprisingly, 48 h post-transfection, there was 
no striking effect on the protein levels of SUMF1 except for CHO cells transfected with si-
SUMF1 as a positive control in which SUMF1 levels were highly depleted (Figure 12A). 
Likewise, SUMF1 mRNA levels showed no significant differences with the scramble control 
except for cgr-miR-377 that showed a significant decrease in SUMF1 mRNA reduction 
compared to scramble control (Figure 12B). However, 72 h post-transfection all antimiRs 
tested showed a significant increase in sulfatase specific activity except for anti-mmu-miR-
377-3p (Figure 11C) with no effect on growth (Figure 11A). In addition, there was no 
significant differences between the sulfatase titer of all antimiRs tested compared to 
scramble except for anti-cgr-miR-377-3p (Figure 11B). Furthermore, as a confirmation of 
functional and efficient transfection of antimiRs and siRNAs, mature miRNA levels analyzed 
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48 h post transfection showed downregulation of endogenous miR-23a and miR-377 
compared to scramble (Figure 12C)  
 
5.3 Discussion 
Mammalian cells has become the traditional and classic cell factories used in the production 
of biopharmaceutical recombinant therapeutic proteins (Dyson 2016) because of their ability 
to make complex glycosylated proteins and familiarity with biotech regulatory bodies. 
Among mammalian cells, CHO cell lines most often represent the mammalian cell of choice 
for their ease of use and reduced susceptibility to viral infection (Berting, Farcet, and Kreil 
2010; Dumont et al. 2016). However, due to growing interest in the demand and 
development of difficult-to-express (DTE) recombinant proteins such as bispecific 
antibodies, fusion proteins, and lysosomal proteins, current CHO cell lines may require 
optimization in order to operate at their optimum capacities. Though cell engineering 
approaches, such as single gene engineering (Onitsuka et al. 2018), has been employed to 
improve CHO cell performance there have been limitations associated with this (Le Fourn 
et al. 2014). Recently, there has been growing interest in the use of miRNAs to engineer 
CHO cells for relevant bioprocess phenotypes (Bratkovič et al. 2012), including applications 
in transient protein expression (Meyer et al. 2017) and cell line development (Fischer et al. 
2017). MiRNAs are short non-coding RNAs that are 18-21 nucleotide long and each miRNA 
regulate gene expression by fine tuning the expression of more than one gene, thereby 
regulating more than one pathway concomitantly (Fischer, Handrick, et al. 2015). Although, 
much of the knowledge about miRNAs have stemmed from research on its regulatory effects 
on diseases (most especially cancer), research on its relevance in cell line engineering for 
the biomanufacturing of recombinant proteins have started gaining credence. MiRNA 
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engineering of CHO cells application has been demonstrated to impact relevant 
bioprocessing phenotypes like apoptosis (Druz et al. 2011), proliferation (N. Barron et al. 
2011), cell specific productivity (Inwood et al. 2017) and metabolism (Kelly et al. 2015). 
Furthermore, current works are looking at using miRNA to engineer mammalian cells 
secreting DTE proteins for desirable and relevant bioprocess phenotypes (Xiao et al. 2015; 
Fischer et al. 2017; Schoellhorn et al. 2017). To our knowledge, this is the first study where 
miRNA has been used to engineer CHO cell line stably expressing a DTE recombinant 
therapeutic lysosomal protein – sulfatase. Lysosomal storage disorders (LSD) are genetic 
diseases caused by the accumulation of lysosomal substrates in the lysosome due to 
mutation in genes encoding lysosomal enzymes responsible for degrading accumulated 
substrates in cells (e.g., glycoaminoglycans –GAGs) (Platt 2018). An example of these 
diseases among others is multiple sulfatase deficiency (MSD) caused by mutations in 
sulfatase modifying factor 1 (SUMF1), a gene that encodes formylglycine –generating 
enzyme (FGE) (Garavelli et al. 2014). Interestingly, SUMF1 has been identified as a direct 
target of non-conserved miR-95 (Frankel et al. 2014). The authors discovered that by 
inhibiting miR-95, residual increase in SUMF1 protein levels in MSD fibroblast cells led to 
an increase in lysosomal sulfatase activity. SUMF1 plays a crucial role in activating 
sulfatases by converting cysteine residue in the consensus sequence of sulfatases to active 
formyl glycine (FGly) (Landgrebe et al. 2003). Although SUMF1 is conserved both in 
prokaryotes and eukaryotes (Landgrebe et al. 2003), miR-95 is only conserved in higher 
mammals but not in mice. In principle, since SUMF1 is conserved there might exist other 
conserved miRNA(s) in mice that might regulate its expression. We sought to identify 
miRNA(s) that regulate SUMF1 and the impact on recombinant therapeutic lysosomal 
sulfatase specific activity in CHO cell.  
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5.3.1 Transient inhibition of miR-23a and miR-377 increases lysosomal recombinant 
sulfatase specific activity in CHO cell 
MiR-23a and miR-377 were identified as putative miRNAs regulating SUMF1 by using in 
silico computational prediction tools: TargetScan, miRanda-mirSVR, Diana-microT-CDS, 
Diana-Tarbase and miRecords. We sought to demonstrate functionally if these miRNAs 
might improve the specific activity of recombinant lysosomal sulfatase constitutively 
expressed in a CHO cell line. Transient inhibition of miR-23a and miR-377 increased the 
specific activity of recombinant lysosomal sulfatase protein by 1.2 – 1.3-fold increase 
compared to negative control scramble (Figure 11C) without affecting cell growth (Figure 
11A). It seems 1.2 – 1.3-fold increase in sulfatase specific activity appears to be moderate 
compared to the scramble control, this could be because transient inhibitory effect of 
antimiRs dwindle over time. In addition, similar fold increase in sulfatase activity has been 
seen after overexpressing SUMF1 gene in a work by Fraldi et al. (2007). In this conjunction, 
a stable inhibition of miR-23a/miR-377 could further boost the specific activity of lysosomal 
sulfatase protein constitutively expressed in CHO cells. Notably, in a different study (Kelly 
et al. 2015), miR-23 was found to enhance the specific productivity of CHO cell expressing 
an easy-to-express human secreted alkaline phosphatase (SEAP) protein without affecting 
cell growth. The authors went further to demonstrate that the increased specific productivity 
of CHO cells after stably inhibiting miR-23 was as a result of enhanced oxidative 
phosphorylation through the TCA cycle. In an earlier study, mitochondrial glutaminase levels 
in human P-493B lymphoma cells and PC3 prostate cancer cells increased after 
downregulation of miR-23a (Gao et al. 2009). Glutamate, which is a product of glutamine 
breakdown in the presence of glutaminase, is funneled via the TCA cycle for ATP production 
which is very vital for protein synthesis. Furthermore, in a different study, overexpression of 
miR-377 caused a 60% reduction in MAP3K7 protein levels (Zehavi et al. 2015) and 
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regulation of MAPK7 gene in CHO by miR-143 has been shown to enhance the expression 
of a DTE protein (Schoellhorn et al. 2017). Hypothetically, after transient inhibition of miR-
23a/miR-377 we expected an increase in SUMF1 mRNA and protein levels instead we 
observed no significant difference in SUMF1 protein (Figure 12A) and mRNA (Figure 12B) 
levels compared to the scramble control. This might be an indication that the right amount 
of SUMF1 as needed by the internal cellular mechanism is just right enough to increase the 
specific activity of recombinant lysosomal sulfatases while inhibiting the effect of 
endogenous miR-23a/miR-377 negatively regulating SUMF1 transcripts. Surprisingly, when 
miR-23a and miR-377 were transiently overexpressed, the SUMF1 protein (Figure 10A) 
and mRNA (Figure 10B) in CHO cells were significantly decreased compared to the 
scramble control. This phenomenon was also confirmed when we performed a titration of 
miR-23a mimics concentration and each concentration resulted in a decrease in mRNA 
(Figure 13C) and protein levels (Figure 13B) of SUMF1 with no effect on growth (Figure 
13A). Though the reduction in mRNA using 10, 50 and 200 nM of miR-23a mimics were not 
significant (Figure 13C) and including 100 nM of miR-23a mimic for protein levels (Figure 
13B). However, the reduction in mRNA and protein levels of SUMF1 as a result of miR-
23a/miR-377 overexpression did not cause any decrease in recombinant lysosomal 
sulfatase specific activity. The explanation could be that there are other internal cellular 
mechanism that maintains a particular threshold of SUMF1 levels (Sardiello et al. 2005) and 
the optimal amount of SUMF1 required to activate sulfatases may vary across the different 
types of lysosomal sulfatases (Fraldi et al. 2007). In our case, the optimal SUMF1 required 
for activation of our sulfatase enzyme of interest might be low which might explain the 
reason there was no change in specific activity of the lysosomal sulfatase following the 
overexpression of miR23a/miR-377. Taken together, these data demonstrate the relevance 
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of miR-23a and miR-377 in cell engineering of CHO cells expressing DTE recombinant 




Availability of data and material: The datasets supporting the conclusions of this article 
are included within the article. 
Funding: This study was funded by BioMarin Pharmaceutical Inc. 
Authors’ contributions: MA, TC, VA, JL participated in the conceptualization of the study 
and contributed to the experimental design and data analysis. MA performed the 
investigation and wrote the manuscript and all authors contributed to its edition.   
Competing interests: MA, TC, VA, JL are employees and TC, VA, JL stockholders of 
BioMarin Pharmaceutical Inc. 
Acknowledgments: The authors would like to thank JL, VA, and TC at BioMarin 
Pharmaceutical Inc. for their valuable suggestions and support throughout the execution of 
the study.  
 
REFERENCES. 
Alves, Christina S., Alan Gilbert, Swati Dalvi, Bryan St Germain, Wenqi Xie, Scott Estes, 
Rashmi Kshirsagar, and Thomas Ryll. 2015. “Integration of Cell Line and Process 
Development to Overcome the Challenge of a Difficult to Express Protein.” 
Biotechnology Progress 31 (5): 1201–11. doi:10.1002/btpr.2091. 
Baek, Daehyun, Judit Villén, Chanseok Shin, Fernando D. Camargo, Steven P. Gygi, and 
David P. Bartel. 2008. “The Impact of microRNAs on Protein Output.” Nature. 




Barron, N., N. Kumar, N. Sanchez, P. Doolan, C. Clarke, P. Meleady, F. O’Sullivan, and 
M. Clynes. 2011. “Engineering CHO Cell Growth and Recombinant Protein 
Productivity by Overexpression of miR-7.” Journal of Biotechnology. 
doi:10.1016/j.jbiotec.2010.12.005. 
Barron, Niall. 2012. MicroRNAs as Tools in Biopharmaceutical Production. MicroRNAs as 
Tools in Biopharmaceutical Production. doi:10.1007/978-94-007-5128-6. 
Berting, Andreas, Maria R. Farcet, and Thomas R. Kreil. 2010. “Virus Susceptibility of 
Chinese Hamster Ovary (CHO) Cells and Detection of Viral Contaminations by 
Adventitious Agent Testing.” Biotechnology and Bioengineering 106 (4): 598–607. 
doi:10.1002/bit.22723. 
Bort, Juan A Hernández, Matthias Hackl, Helga Höflmayer, Vaibhav Jadhav, Eva 
Harreither, Niraj Kumar, Wolfgang Ernst, Johannes Grillari, and Nicole Borth. 2012. 
“Dynamic mRNA and miRNA Profiling of CHO-K1 Suspension Cell Cultures.” 
Biotechnology Journal 7 (4): 500–515. doi:10.1002/biot.201100143. 
Bratkovič, Tomaž, Gordana Glavan, Borut Štrukelj, Marko Živin, and Boris Rogelj. 2012. 
“Exploiting microRNAs for Cell Engineering and Therapy.” Biotechnology Advances. 
doi:10.1016/j.biotechadv.2012.01.006. 
Buchsteiner, Maria, Lake-Ee Quek, Peter Gray, and Lars K. Nielsen. 2018. “Improving 
Culture Performance and Antibody Production in CHO Cell Culture Processes by 
Reducing the Warburg Effect.” Biotechnology and Bioengineering, no. April: 2315–27. 
doi:10.1002/bit.26724. 
Carter, Jane, Jue Zhang, Thien Lan Dang, Haruki Hasegawa, Janet D. Cheng, Irene 
Gianan, Jason W. O’Neill, et al. 2010. “Fusion Partners Can Increase the Expression 
of Recombinant Interleukins via Transient Transfection in 2936E Cells.” Protein 
Science 19 (2): 357–62. doi:10.1002/pro.307. 
Chen, Caifu, Dana A. Ridzon, Adam J. Broomer, Zhaohui Zhou, Danny H. Lee, Julie T. 
Nguyen, Maura Barbisin, et al. 2005. “Real-Time Quantification of microRNAs by 
Stem-Loop RT-PCR.” Nucleic Acids Research. doi:10.1093/nar/gni178. 
Cho, Joon Ho, Manjari Dimri, and Goberdhan P. Dimri. 2015. “MicroRNA-31 Is a 
Transcriptional Target of Histone Deacetylase Inhibitors and a Regulator of Cellular 
Senescence.” Journal of Biological Chemistry 290 (16): 10555–67. 
doi:10.1074/jbc.M114.624361. 
Clarke, Colin, Michael Henry, Padraig Doolan, Shane Kelly, Sinead Aherne, Noelia 
Sanchez, Paul Kelly, et al. 2012. “Integrated miRNA, mRNA and Protein Expression 
Analysis Reveals the Role of Post-Transcriptional Regulation in Controlling CHO Cell 
Growth Rate.” BMC Genomics. doi:10.1186/1471-2164-13-656. 
Clincke, Marie Françoise, Emmanuel Guedon, Frances T. Yen, Virginie Ogier, Olivier 
Roitel, and Jean Louis Goergen. 2011. “Effect of Surfactant Pluronic F-68 on CHO 
DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD
95 
 
Cell Growth, Metabolism, Production, and Glycosylation of Human Recombinant IFN-
γ in Mild Operating Conditions.” Biotechnology Progress 27 (1): 181–90. 
doi:10.1002/btpr.503. 
Derouazi, M., D. Martinet, N. Besuchet Schmutz, R. Flaction, M. Wicht, M. Bertschinger, 
D. L. Hacker, J. S. Beckmann, and F. M. Wurm. 2006. “Genetic Characterization of 
CHO Production Host DG44 and Derivative Recombinant Cell Lines.” Biochemical 
and Biophysical Research Communications 340 (4): 1069–77. 
doi:10.1016/j.bbrc.2005.12.111. 
Desnick, R.J., and E.H. Schuchman. 2012. Enzyme Replacement Therapy for Lysosomal 
Diseases: Lessons from 20 Years of Experience and Remaining Challenges. Annual 
Review of Genomics and Human Genetics. Vol. 13. doi:10.1146/annurev-genom-
090711-163739. 
Dorai, Haimanti, Dawn Ellis, Yun Seung Keung, Marguerite Campbell, Minhong Zhuang, 
Chengbin Lin, and Michael J. Betenbaugh. 2010. “Combining High-Throughput 
Screening of Caspase Activity with Anti-Apoptosis Genes for Development of Robust 
CHO Production Cell Lines.” Biotechnology Progress 26 (5): 1367–81. 
doi:10.1002/btpr.426. 
Druz, Aliaksandr, Chia Chu, Brian Majors, Rodell Santuary, Michael Betenbaugh, and 
Joseph Shiloach. 2011. “A Novel microRNA Mmu-miR-466h Affects Apoptosis 
Regulation in Mammalian Cells.” Biotechnology and Bioengineering. 
doi:10.1002/bit.23092. 
Druz, Aliaksandr, Young Jin Son, Michael Betenbaugh, and Joseph Shiloach. 2013. 
“Stable Inhibition of Mmu-miR-466h-5p Improves Apoptosis Resistance and Protein 
Production in CHO Cells.” Metabolic Engineering. doi:10.1016/j.ymben.2012.12.004. 
Dumont, Jennifer, Don Euwart, Baisong Mei, Scott Estes, and Rashmi Kshirsagar. 2016. 
“Human Cell Lines for Biopharmaceutical Manufacturing: History, Status, and Future 
Perspectives.” Critical Reviews in Biotechnology 36 (6): 1110–22. 
doi:10.3109/07388551.2015.1084266. 
Dyson, Michael R. 2016. “Fundamentals of Expression in Mammalian Cells.” In Advanced 
Technologies for Protein Complex Production and Characterization, edited by M 
Cristina Vega, 217–24. Cham: Springer International Publishing. doi:10.1007/978-3-
319-27216-0_14. 
Emmerling, Verena V., Simon Fischer, Fabian Stiefel, Karlheinz Holzmann, René 
Handrick, Friedemann Hesse, Markus Hörer, Stefan Kochanek, and Kerstin Otte. 
2016. “Temperature-Sensitive miR-483 Is a Conserved Regulator of Recombinant 
Protein and Viral Vector Production in Mammalian Cells.” Biotechnology and 
Bioengineering. doi:10.1002/bit.25853. 
Fischer, Simon, René Handrick, Armaz Aschrafi, and Kerstin Otte. 2015. “Unveiling the 
Principle of microRNA-Mediated Redundancy in Cellular Pathway Regulation.” RNA 
Biology. doi:10.1080/15476286.2015.1017238. 
DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD
96 
 
Fischer, Simon, Kim F Marquart, Lisa A Pieper, Juergen Fieder, Martin Gamer, Ingo Gorr, 
Patrick Schulz, and Harald Bradl. 2017. “miRNA Engineering of CHO Cells Facilitates 
Production of Difficult-to-Express Proteins and Increases Success in Cell Line 
Development.” Biotechnol. Bioeng 9999: 1–16. doi:10.1002/bit.26280. 
Fischer, Simon, Albert Jesuran Paul, Andreas Wagner, Sven Mathias, Melanie Geiss, 
Franziska Schandock, Martin Domnowski, et al. 2015. “miR-2861 as Novel HDAC5 
Inhibitor in CHO Cells Enhances Productivity While Maintaining Product Quality.” 
Biotechnology and Bioengineering 112 (10): 2142–53. doi:10.1002/bit.25626. 
Fischer, Simon, Andreas Wagner, Aron Kos, Armaz Aschrafi, René Handrick, Juergen 
Hannemann, and Kerstin Otte. 2013. “Breaking Limitations of Complex Culture 
Media: Functional Non-Viral miRNA Delivery into Pharmaceutical Production Cell 
Lines.” Journal of Biotechnology 168 (4). Elsevier B.V.: 589–600. 
doi:10.1016/j.jbiotec.2013.08.027. 
Fliedl, Lukas, Johannes Grillari, and Regina Grillari-Voglauer. 2015. “Human Cell Lines for 
the Production of Recombinant Proteins: On the Horizon.” New Biotechnology 32 (6). 
Elsevier B.V.: 673–79. doi:10.1016/j.nbt.2014.11.005. 
Fourn, Valérie Le, Pierre Alain Girod, Montse Buceta, Alexandre Regamey, and Nicolas 
Mermod. 2014. “CHO Cell Engineering to Prevent Polypeptide Aggregation and 
Improve Therapeutic Protein Secretion.” Metabolic Engineering 21: 91–102. 
doi:10.1016/j.ymben.2012.12.003. 
Fraldi, Alessandro, Alessandra Biffi, Alessia Lombardi, Ilaria Visigalli, Stefano Pepe, 
Carmine Settembre, Edoardo Nusco, et al. 2007. “SUMF1 Enhances Sulfatase 
Activities in Vivo in Five Sulfatase Deficiencies.” Biochemical Journal 403 (2): 305–
12. doi:10.1016/j.compositesa.2016.12.003. 
Frankel, Lisa B., Chiara Di Malta, Jiayu Wen, Eeva-Liisa Eskelinen, Andrea Ballabio, and 
Anders H. Lund. 2014. “A Non-Conserved miRNA Regulates Lysosomal Function 
and Impacts on a Human Lysosomal Storage Disorder.” Nature Communications. 
doi:10.1038/ncomms6840. 
Gagnon, Matthew, Gregory Hiller, Yen Tung Luan, Amy Kittredge, Jordy Defelice, and 
Denis Drapeau. 2011. “High-End pH-Controlled Delivery of Glucose Effectively 
Suppresses Lactate Accumulation in CHO Fed-Batch Cultures.” Biotechnology and 
Bioengineering 108 (6): 1328–37. doi:10.1002/bit.23072. 
Galatenko, Vladimir V., Alexey V. Galatenko, Timur R. Samatov, Andrey A. Turchinovich, 
Maxim Yu Shkurnikov, Julia A. Makarova, and Alexander G. Tonevitsky. 2018. 
“Comprehensive Network of miRNA-Induced Intergenic Interactions and a Biological 
Role of Its Core in Cancer.” Scientific Reports 8 (1): 1–12. doi:10.1038/s41598-018-
20215-5. 
Gao, Ping, Irina Tchernyshyov, Tsung Cheng Chang, Yun Sil Lee, Kayoko Kita, Takafumi 
Ochi, Karen I. Zeller, et al. 2009. “C-Myc Suppression of miR-23a/b Enhances 
Mitochondrial Glutaminase Expression and Glutamine Metabolism.” Nature 458 
(7239). Nature Publishing Group: 762–65. doi:10.1038/nature07823. 
DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD
97 
 
Garavelli, Livia, Lucia Santoro, Alexandra Iori, Giancarlo Gargano, Silvia Braibanti, 
Simona Pedori, Nives Melli, et al. 2014. “Multiple Sulfatase Deficiency with Neonatal 
Manifestation.” Italian Journal of Pediatrics 40: 86. doi:10.1186/s13052-014-0086-2. 
Ha, Minju, and V. Narry Kim. 2014. “Regulation of microRNA Biogenesis.” Nature Reviews 
Molecular Cell Biology. doi:10.1038/nrm3838. 
Hackl, Matthias, Vaibhav Jadhav, Gerald Klanert, Michael Karbiener, Marcel Scheideler, 
Johannes Grillari, and Nicole Borth. 2014. “Analysis of microRNA Transcription and 
Post-Transcriptional Processing by Dicer in the Context of CHO Cell Proliferation.” 
Journal of Biotechnology 190. Elsevier B.V.: 76–84. 
doi:10.1016/j.jbiotec.2013.12.018. 
Hackl, Matthias, Tobias Jakobi, Jochen Blom, Daniel Doppmeier, Karina Brinkrolf, Rafael 
Szczepanowski, Stephan H Bernhart, et al. 2011. “Next-Generation Sequencing of 
the Chinese Hamster Ovary microRNA Transcriptome : Identification , Annotation and 
Profiling of microRNAs as Targets for Cellular Engineering ଝ.” Journal of 
Biotechnology 153 (1–2). Elsevier B.V.: 62–75. doi:10.1016/j.jbiotec.2011.02.011. 
Hammond, Stephanie, Jeffrey C Swanberg, Shawn W Polson, and Kelvin H Lee. 2012. 
“Profiling Conserved MicroRNA Expression in Recombinant CHO Cell Lines Using 
Illumina Sequencing.” Biotechnology and Bioengineering 109 (6): 1371–75. 
doi:10.1002/bit.24415. 
Harreither, Eva, Matthias Hackl, Johannes Pichler, Smriti Shridhar, Norbert Auer, Pawelł 
P. Łabaj, Marcel Scheideler, et al. 2015. “Microarray Profiling of Preselected CHO 
Host Cell Subclones Identifies Gene Expression Patterns Associated with in-Creased 
Production Capacity.” Biotechnology Journal 10 (10): 1625–38. 
doi:10.1002/biot.201400857. 
Harreither et al. 2015. “Microarray Profiling of Preselected CHO Host Cell Subclones 
Identifies Gene Expression Patterns Associated with Increased Production Capacity.” 
Biotechnology Journal 10: 1625–38. DOI 10.1002/biot.201400857. 
Huang, Yao Ming, Wei Wei Hu, Eddie Rustandi, Kevin Chang, Helena Yusuf-
Makagiansar, and Thomas Ryll. 2010. “Maximizing Productivity of CHO Cell-Based 
Fed-Batch Culture Using Chemically Defined Media Conditions and Typical 
Manufacturing Equipment.” Biotechnology Progress 26 (5): 1400–1410. 
doi:10.1002/btpr.436. 
Hurd, Paul J., and Christopher J. Nelson. 2009. “Advantages of next-Generation 
Sequencing versus the Microarray in Epigenetic Research.” Briefings in Functional 
Genomics and Proteomics 8 (3): 174–83. doi:10.1093/bfgp/elp013. 
Inwood, Sarah, Michael Betenbaugh, and Joseph Shiloach. 2018. “Methods for Using 
Small Non-Coding RNAs to Improve Recombinant Protein Expression in Mammalian 
Cells.” Genes 9 (1): 25. doi:10.3390/genes9010025. 
Inwood, Sarah, Eugen Buehler, Michael Betenbaugh, Madhu Lal, and Joseph Shiloach. 
2017. “Identifying HIPK1 as Target of miR-22-3p Enhancing Recombinant Protein 
DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD
98 
 
Production From HEK 293 Cell by Using Microarray and HTP siRNA Screen.” 
Biotechnology Journal 1700342: 1–9. doi:10.1002/biot.201700342. 
Ioannou, Y. A., D. F. Bishop, and R. J. Desnick. 1992. “Overexpression of Human α-
Galactosidase A Results in Its Intracellular Aggregation, Crystallization in Lysosomes, 
and Selective Secretion.” Journal of Cell Biology 119 (5): 1137–50. 
doi:10.1083/jcb.119.5.1137. 
J. Robin Lytle, Therese A. Yario, and Joan A. Steitz*. 2000. “Learning and Circadian 
Behavior.” Journal of Biological Rhythms 15 (4): 296–99. 
doi:10.1177/074873000129001396. 
Jadhav, Vaibhav, Matthias Hackl, Aliaksandr Druz, Smriti Shridhar, Cheng Yu Chung, 
Kelley M. Heffner, David P. Kreil, et al. 2013. “CHO microRNA Engineering Is 
Growing up: Recent Successes and Future Challenges.” Biotechnology Advances 31 
(8). The Authors: 1501–13. doi:10.1016/j.biotechadv.2013.07.007. 
Jadhav, Vaibhav, Matthias Hackl, Juan A. Hernandez Bort, Matthias Wieser, Eva 
Harreither, Renate Kunert, Nicole Borth, and Johannes Grillari. 2012. “A Screening 
Method to Assess Biological Effects of microRNA Overexpression in Chinese 
Hamster Ovary Cells.” Biotechnology and Bioengineering. doi:10.1002/bit.24490. 
Jazayeri, Seyedeh Hoda, Amir Amiri-Yekta, Salahadin Bahrami, Hamid Gourabi, 
Mohammad Hossein Sanati, and Mohammad Reza Khorramizadeh. 2018. “Vector 
and Cell Line Engineering Technologies Toward Recombinant Protein Expression in 
Mammalian Cell Lines.” Applied Biochemistry and Biotechnology 185 (4). Applied 
Biochemistry and Biotechnology: 986–1003. doi:10.1007/s12010-017-2689-8. 
Johari, Yusuf B., Scott D. Estes, Christina S. Alves, Marty S. Sinacore, and David C. 
James. 2015. “Integrated Cell and Process Engineering for Improved Transient 
Production of A ‘difficult-to-Express’ fusion Protein by CHO Cells.” Biotechnology and 
Bioengineering. doi:10.1002/bit.25687. 
Kelly, Paul S., Laura Breen, Clair Gallagher, Shane Kelly, Michael Henry, Nga T. Lao, 
Paula Meleady, Donal O’Gorman, Martin Clynes, and Niall Barron. 2015. “Re-
Programming CHO Cell Metabolism Using miR-23 Tips the Balance towards a Highly 
Productive Phenotype.” Biotechnology Journal. doi:10.1002/biot.201500101. 
Kelly, Paul S, Colin Clarke, Martin Clynes, and Niall Barron. 2014. “Bioprocess 
Engineering: Micromanaging Chinese Hamster Ovary Cell Phenotypes.” Pharm. 
Bioprocess 2 (4): 323–37. doi:10.4155/PBP.14.28. 
Klanert, Gerald, Vaibhav Jadhav, Vinoth Shanmukam, Andreas Diendorfer, Michael 
Karbiener, Marcel Scheideler, Juan Hern??ndez Bort, Johannes Grillari, Matthias 
Hackl, and Nicole Borth. 2016. “A Signature of 12 microRNAs Is Robustly Associated 
with Growth Rate in a Variety of CHO Cell Lines.” Journal of Biotechnology. 
doi:10.1016/j.jbiotec.2016.03.022. 
Kyriakis, John M., and Joseph Avruch. 2001. “Mammalian Mitogen-Activated Protein 
Kinase Signal Transduction Pathways Activated by Stress and Inflammation.” 
DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD
99 
 
Physiological Reviews 81 (2): 807–69. doi:10.1152/physrev.2001.81.2.807. 
Landgrebe, Jobst, Thomas Dierks, Bernhard Schmidt, and Kurt Von Figura. 2003. “The 
Human SUMF1 Gene, Required for Posttranslational Sulfatase Modification, Defines 
a New Gene Family Which Is Conserved from pro- to Eukaryotes.” Gene 316 (1–2): 
47–56. doi:10.1016/S0378-1119(03)00746-7. 
Lee, Frank W F, Cynthia B Elias, Paul Todd, and Dhinakar S Kompala. 1998. “Engineering 
Chinese Hamster Ovary (CHO) Cells to Achieve an Inverse Growth – Associated 
Production of a Foreign Protein, β-Galactosidase.” Cytotechnology 28: 73–80. 
doi:10.1023/A:1008069312131. 
Liu, Lin, Wang Sik Lee, Balraj Doray, and Stuart Kornfeld. 2017. “Engineering of GlcNAc-
1-Phosphotransferase for Production of Highly Phosphorylated Lysosomal Enzymes 
for Enzyme Replacement Therapy.” Molecular Therapy - Methods and Clinical 
Development 5 (June). Elsevier Ltd.: 59–65. doi:10.1016/j.omtm.2017.03.006. 
Loh, Wan Ping, Bernard Loo, Lihan Zhou, Peiqing Zhang, Dong Yup Lee, Yuansheng 
Yang, and Kong Peng Lam. 2014. “Overexpression of microRNAs Enhances 
Recombinant Protein Production in Chinese Hamster Ovary Cells.” Biotechnology 
Journal 9 (9): 1140–51. doi:10.1002/biot.201400050. 
Loh, Wan Ping, Yuansheng Yang, and Kong Peng Lam. 2017. “miR-92a Enhances 
Recombinant Protein Productivity in CHO Cells by Increasing Intracellular Cholesterol 
Levels.” Biotechnology Journal 12 (4): 1–11. doi:10.1002/biot.201600488. 
Maccani, Andreas, Matthias Hackl, Christian Leitner, Willibald Steinfellner, Alexandra B. 
Graf, Nadine E. Tatto, Michael Karbiener, et al. 2014. “Identification of microRNAs 
Specific for High Producer CHO Cell Lines Using Steady-State Cultivation.” Applied 
Microbiology and Biotechnology 98 (17): 7535–48. doi:10.1007/s00253-014-5911-4. 
Meleady, Paula, Padraig Doolan, Michael Henry, Niall Barron, Joanne Keenan, Finbar 
O’Sullivan, Colin Clarke, et al. 2011. “Sustained Productivity in Recombinant Chinese 
Hamster Ovary (CHO) Cell Lines: Proteome Analysis of the Molecular Basis for a 
Process-Related Phenotype.” BMC Biotechnology 11 (1). BioMed Central Ltd: 78. 
doi:10.1186/1472-6750-11-78. 
Meyer, Hermann Josef, Dorothea Reilly, Scott E. Martin, and Athena W. Wong. 2017. 
“Identification of a Novel miRNA That Increases Transient Protein Expression in 
Combination with Valproic Acid.” Biotechnology Progress 33 (4): 1139–45. 
doi:10.1002/btpr.2488. 
Migani, Damiano, C Mark Smales, and Daniel G Bracewell. 2017. “Effects of Lysosomal 
Biotherapeutic Recombinant Protein Expression on Cell Stress and Protease and 
General Host Cell Protein Release in Chinese Hamster Ovary Cells.” 
doi:10.1002/btpr.2455. 
Monger, Craig, Paul S. Kelly, Clair Gallagher, Martin Clynes, Niall Barron, and Colin 
Clarke. 2015. “Towards next Generation CHO Cell Biology: Bioinformatics Methods 
for RNA-Seq-Based Expression Profiling.” Biotechnology Journal 10 (7): 950–66. 




O’Brien, Jacob, Heyam Hayder, Yara Zayed, and Chun Peng. 2018. “Overview of 
MicroRNA Biogenesis, Mechanisms of Actions, and Circulation.” Frontiers in 
Endocrinology 9 (August): 1–12. doi:10.1097/IJG.0b013e31815a343b. 
Onitsuka, Masayoshi, Yukie Kinoshita, Akitoshi Nishizawa, Tomomi Tsutsui, and Takeshi 
Omasa. 2018. “Enhanced IgG1 Production by Overexpression of Nuclear Factor 
Kappa B Inhibitor Zeta (NFKBIZ) in Chinese Hamster Ovary Cells.” Cytotechnology 
70 (2). Springer Netherlands: 675–85. doi:10.1007/s10616-017-0170-8. 
Pasquinelli, Amy E. 2012. “MicroRNAs and Their Targets: Recognition, Regulation and an 
Emerging Reciprocal Relationship.” Nature Reviews. Genetics 13 (4). Nature 
Publishing Group: 271–82. doi:10.1038/nrg3162. 
Platt, Frances M. 2018. “Emptying the Stores: Lysosomal Diseases and Therapeutic 
Strategies.” Nature Reviews Drug Discovery 17 (2). Nature Publishing Group: 133–
50. doi:10.1038/nrd.2017.214. 
Pritchard, Colin C., Heather H. Cheng, and Muneesh Tewari. 2012. “MicroRNA Profiling: 
Approaches and Considerations.” Nature Reviews Genetics. doi:10.1038/nrg3198. 
Pybus, Leon P., Greg Dean, Nathan R. West, Andrew Smith, Olalekan Daramola, Ray 
Field, Stephen J. Wilkinson, and David C. James. 2014. “Model-Directed Engineering 
Of ‘difficult-to-Express’ monoclonal Antibody Production by Chinese Hamster Ovary 
Cells.” Biotechnology and Bioengineering. doi:10.1002/bit.25116. 
Queiroz, Matheus Trovão de, Vanessa Gonçalves Pereira, Cinthia Castro do Nascimento, 
and Vânia D’Almeida. 2016. “The Underexploited Role of Non-Coding RNAs in 
Lysosomal Storage Diseases.” Frontiers in Endocrinology 7 (SEP): 1–5. 
doi:10.3389/fendo.2016.00133. 
Rajendra, Yashas, Robert B. Peery, and Gavin C. Barnard. 2016. “Generation of Stable 
Chinese Hamster Ovary Pools Yielding Antibody Titers of up to 7.6 g/L Using the 
piggyBac Transposon System.” Biotechnology Progress 32 (5): 1301–7. 
doi:10.1002/btpr.2307. 
Sardiello, M., I. Annunziata, G. Roma, and A. Ballabio. 2005. “Sulfatases and Sulfatase 
Modifying Factors: An Exclusive and Promiscuous Relationship.” Human Molecular 
Genetics 14 (21): 3203–17. doi:10.1093/hmg/ddi351. 
Scarcelli, John J., Megan Hone, Kathryn Beal, Alejaida Ortega, Bruno Figueroa, Jason A. 
Starkey, and Karin Anderson. 2018. “Analytical Subcloning of a Clonal Cell Line 
Demonstrates Cellular Heterogeneity That Does Not Impact Process Consistency or 
Robustness.” Biotechnology Progress 34 (3): 602–12. doi:10.1002/btpr.2646. 
Schmittgen, Thomas D, and Kenneth J Livak. 2008. “Analyzing Real-Time PCR Data by 
the Comparative CT Method.” Nature Protocols 3 (6): 1101–8. 
doi:10.1038/nprot.2008.73. 
DocuSign Envelope ID: 3C6E5F98-0102-4945-8860-6D2BC9FFBDFD
101 
 
Schoellhorn, Melanie, Simon Fischer, Andreas Wagner, Ren E Handrick, and Kerstin Otte. 
2017. “miR-143 Targets MAPK7 in CHO Cells and Induces a Hyperproductive 
Phenotype to Enhance Production of Difficult-to-Express Proteins.” 
doi:10.1002/btpr.2475. 
Stiefel, Fabian, Simon Fischer, Alexander Sczyrba, Kerstin Otte, and Friedemann Hesse. 
2016. “MiRNA Profiling of High, Low and Non-Producing CHO Cells during Biphasic 
Fed-Batch Cultivation Reveals Process Relevant Targets for Host Cell Engineering.” 
Journal of Biotechnology. doi:10.1016/j.jbiotec.2016.03.028. 
Strotbek, Michaela, Lore Florin, Jennifer Koenitzer, Anne Tolstrup, Hitto Kaufmann, 
Angelika Hausser, and Monilola A Olayioye. 2013. “Stable microRNA Expression 
Enhances Therapeutic Antibody Productivity of Chinese Hamster Ovary Cells.” 
Metabolic Engineering 20: 157–66. doi:10.1016/j.ymben.2013.10.005. 
Thomson, Daniel W., Cameron P. Bracken, Jan M. Szubert, and Gregory J. Goodall. 
2013. “On Measuring miRNAs after Transient Transfection of Mimics or Antisense 
Inhibitors.” PLoS ONE 8 (1): 1–7. doi:10.1371/journal.pone.0055214. 
Vasudevan, Shobha. 2012. “Posttranscriptional Upregulation by MicroRNAs.” Wiley 
Interdisciplinary Reviews: RNA 3 (3): 311–30. doi:10.1002/wrna.121. 
Wang, Zhiwei, Wenyi Wei, and Fazlul H. Sarkar. 2012. “miR-23a, a Critical Regulator of 
‘migR’ation and Metastasis in Colorectal Cancer.” Cancer Discovery 2 (6): 489–91. 
doi:10.1158/2159-8290.CD-12-0177. 
Winter, Julia, Stephanie Jung, Sarina Keller, Richard I. Gregory, and Sven Diederichs. 
2009. “Many Roads to Maturity: microRNA Biogenesis Pathways and Their 
Regulation.” Nature Cell Biology. doi:10.1038/ncb0309-228. 
Xiao, Su, Yu Chi Chen, Michael J. Betenbaugh, Scott E. Martin, and Joseph Shiloach. 
2015. “MiRNA Mimic Screen for Improved Expression of Functional Neurotensin 
Receptor from HEK 293 Cells.” Biotechnology and Bioengineering 112 (8): 1632–43. 
doi:10.1002/bit.25567. 
Zehavi, Liron, Hagit Schayek, Jasmine Jacob-Hirsch, Yechezkel Sidi, Raya Leibowitz-
Amit, and Dror Avni. 2015. “MiR-377 Targets E2F3 and Alters the NF-kB Signaling 




















Figure 8: Characterization of different mammalian cells to determine appropriate SUMF1 antibody 
(A) Western blot detection of endogenous SUMF1 protein 72 h post transfection. In addition, 
SUMF1 protein detection in CHO-sulfatase cell stably expressing human SUMF1 was also tested 
(B) Predicted binding sites of miR-23a and miR-377 on SUMF1 3’ UTR. Bases in red represents 
the binding site of the miRNAs seed region to the 3’ UTR of SUMF1 (TargetScan.org).  
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V i a b i l i t y
  
Figure 9: Transient transfection of 50 nM miR-23a and miR-377 mimics in CHO suspension cells 
stably expressing a recombinant difficult-to-express (DTE) lysosomal sulfatase protein. Cells were 
cultured in a 6-well plate using a batch process and kept in a static incubator. (A) Viable cell density 
(VCD) and viability 72 h post transfection (B) Sulfatase titer and (C) specific activity determined by 
an Elisa and activity assay respectively. Samples were taken from the culture supernatants 72 h 
post-transfection and data represented as fold change normalized to scramble (NT-siRNA) control. 
Anti-SUMF1 siRNA (si-SUMF1) was used as a positive control. Error bars represent the standard 
error of mean (SEM) of three independent experiments (n=3). For statistical analysis, one-way 
ANOVA comparing the mean values of the mimics (*** P < 0.001).  
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Figure 10: Functional validation of SUMF1 as a putative target of miR-23a and miR-377 using 
Western blot and quantitative real-time PCR (qRT-PCR) analyses. Cells were transiently 
transfected with 50 nM of miR-23a and miR-377 mimics in CHO suspension cells stably expressing 
a recombinant difficult-to-express (DTE) lysosomal sulfatase protein and cell lysates harvested 48 h 
post-transfection. (A) Western blot showing SUMF1 protein levels and relative densitometry signal 
values of SUMF1 protein levels relative to GAPDH (B) Endogenous SUMF1 mRNA levels post-
transfection relative to scramble (NT-siRNA) non-targeting control. SUMF1 expression was 
normalized to GAPDH (C) Endogenous miR-23a and miR-377 levels post-transfection relative to 
scramble. MiRNA expression was normalized to U6 snoRNA. Anti-SUMF1 siRNA (si-SUMF1) was 
used as a positive control. Error bars represent the standard error of mean (SEM) of three 
independent experiments (n=3). For statistical analysis, one-way ANOVA comparing the mean 






























































































































































































































































































































































































































cgr-miR-23a-3p ATCACATTGCCAGGGATTTCC  
|||||||||||||||||||||
mmu-miR-23a-3p ATCACATTGCCAGGGATTTCC  





Figure 11: Transient transfection of 50 nM miR-23a and miR-377 antimiRs in (targeting either 
endogenous mouse or CHO miR-23a or miR-377) CHO suspension cells stably expressing a 
recombinant difficult-to-express (DTE) lysosomal sulfatase protein. Cells were cultured in a 6-well 
plate using a batch process and kept in a static incubator. (A) Viable cell density (VCD) and viability 
72 h post transfection (B) Sulfatase titer and (C) specific activity determined by an Elisa and activity 
assay respectively. Samples were taken from the culture supernatants 72 h post-transfection and 
data represented as fold change normalized to scramble (NT-siRNA) control. Anti-SUMF1 siRNA 
(si-SUMF1) was used as a positive control. Error bars represent the standard error of mean (SEM) 
of three independent experiments (n=3). For statistical analysis, one-way ANOVA comparing the 
mean values of the (* P < 0.05; ** P < 0.01; *** P < 0.001). 
 
 































































































































































































































































































































































































































































Figure 12: Effect of transient transfection of 50 nM miR-23a and miR-377 antimiRs in (targeting 
either endogenous mouse or CHO miR-23a or miR-377) CHO suspension cells stably expressing a 
recombinant difficult-to-express (DTE) lysosomal sulfatase protein using Western blot and 
quantitative real-time PCR (qRT-PCR) analyses. (A) Western blot of SUMF1 protein levels and 
relative densitometry signal values of SUMF1 protein levels relative to GAPDH 48 h post 
transfection (B) Endogenous SUMF1 mRNA levels post-transfection relative to scramble (NT-
siRNA) non-targeting control. SUMF1 expression was normalized to GAPDH (C) Endogenous miR-
23a and miR-377 levels 48 h post-transfection relative to scramble. miRNA expression was 
normalized to U6 snoRNA. Anti-SUMF1 siRNA (si-SUMF1) was used as a positive control. Error 
bars represent the standard error of mean (SEM) of three independent experiments (n=3). Error 
bars represent the standard error of mean (SEM) of three independent experiments (n=3). For 
statistical analysis, one-way ANOVA comparing the mean values of the (* P < 0.05; ** P < 0.01; *** 























































































































































































































































Figure 13: Transient transfection of titrated concentration (10-200 nM) of cgr-miR-23a mimics in 
CHO suspension cells stably expressing a recombinant difficult-to-express (DTE) lysosomal 
sulfatase protein. Cells were cultured in a 6-well plate using a batch process and kept in a static 
incubator. (A) Upper panel: Viable cell density (VCD). Lower Panel: Viability. Both 72 h post-
transfection (B) Western blot of SUMF1 protein levels and densitometry signal values of SUMF1 
protein levels relative to GAPDH 48 h post transfection (C) Endogenous SUMF1 mRNA levels post-
transfection relative to scramble (NT-siRNA) non-targeting control. SUMF1 expression was 
normalized to GAPDH (D) Endogenous miR-23a levels 48 h post-transfection relative to scramble. 
miRNA expression was normalized to U6 snoRNA. Anti-SUMF1 siRNA (si-SUMF1) was used as a 
positive control. Data are mean +/- SEM of two independent experiment. For statistical analysis, 
unpaired two-tailed t-test was applied (* P < 0.05; ** P < 0.01). 




Supporting Information.  
Table 16: Primers used for miRNA and mRNA expression analyses using qRT-PCR 
Gene ID Forward primer (5’ – 3’) Reverse Primer (5’ – 3’) 
GAPDH AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC 
U6 snoRNA CTCGCTTCGGCAGCACA AACGCTTCACGAATTTGCGT 
SUMF1  TACCTGTCAAAGGCGCTAAC CATTCCAGGAGACATGGAGAAC 
cgr-miR-23a-3p AUCACAUUGCCAGGGAUUUCC Qiagen universal reverse 
primer 
mmu-miR-23a-3p AUCACAUUGCCAGGGAUUUCC Qiagen universal reverse 
primer 
cgr-miR-377-3p UGAAUCACACAAAGGCAACUUUU Qiagen universal reverse 
primer 
























Supporting Information  
Table 17: MiRNAs predicted to target SUMF1 gene in mouse  
Prediction tools used: TargetScan (v.7.1), miRanda-mirSVR (Aug’10), Diana-microT-CDS (v5.0), 
Diana-Tarbase (v.8) in combination with miRecords (April 27, 2013) 
miRecords predicted 234 mouse miRNAs which includes 62 mouse miRNAs predicted altogether 
by the 4 tools to target SUMF1. MiRNAs in “red” were the miRNAs predicted by at least 4 tools 
and were selected for further downstream analyses. Only data for miR-23a-3p and miR-377-3p is 
reported. 
miR-21 miR-377-3p miR-6373 
miR-590-5p miR-882 miR-690 
miR-590-3p miR-185-5p miR-743a-3p 
miR-329 miR-504 miR-497b 
miR-362-3p miR-133a-3p miR-1896 
miR-181a-5p miR-133b-3p miR-350-3p 
miR-181b miR-133c miR-7240-5p 
miR-181c miR-215-3p miR-350-5p 
miR-181d miR-7227-3p miR-291b-3p 
miR-23a-3p miR-669e-3p miR-7094-3p 
miR-23b miR-330-3p miR-1224-3p 
miR-124-3p miR-6911-3p miR-7036b-3p 
miR-106a-5p     not in found CHO miR-3074-5p miR-7002-5p 
miR-106b-5p miR-5625-3p miR-743b-5p    not in found CHO 
miR-17-5p miR-875-3p     not in found CHO miR-6403 
miR-20a miR-3473a miR-300-3p 
miR-20b-5p miR-3473c miR-204-5p 
miR-93-5p miR-7678-3p miR-29-5p 
miR-290-5p miR-3082-3p miR-22-3p 
miR-292-5p miR-3089-3p miR-381-3p 
miR-3470b miR-155-5p 
 








Figure 14: si-hSUMF1 was titrated to determine the optimal concentration that will reduce or 
completely delete exogenously hSUMF1 stably expressed in CHO cell line secreting a sulfatase: A) 
Western blot analysis of different concentration of si-hSUMF1 and volume of transfection reagent 
used. B) Relative signal intensity of hSUMF1 levels in CHO cell line exogenously expressing 
hSUMF1 compared to mock, scramble and untransfected cells. 
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